SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 21, 2003
----------
MANHATTAN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-27282 36-3898269
(State or other jurisdiction of (Commission file number) (I.R.S. employer
incorporation or organization) identification no.)
350 Fifth Avenue
Suite 5507 10118
New York, New York (Zip code)
(Address of principal executive offices)
Registrant's telephone number, including area code: (212) 267-2503
Item 2. Acquisition of Disposition of Assets.
On February 21, 2003, Manhattan Pharmaceuticals, Inc., a Delaware
corporation formerly known as Atlantic Technology Ventures, Inc.
("Manhattan"), completed the acquisition of Manhattan Research Development
Corp., a privately held Delaware corporation formerly known as Manhattan
Pharmaceuticals, Inc. ("Manhattan Research"). In accordance with the terms
of a merger agreement dated as of December 17, 2002, Manhattan
Pharmaceuticals Acquisition Corp., a Delaware corporation and a wholly-owned
subsidiary of Manhattan, merged into Manhattan Research, with Manhattan
Research remaining as the surviving corporation.
As a result of the merger, each outstanding share of Manhattan Research
was converted into the right to receive approximately 13 shares of Manhattan
common stock. In connection with the merger, former holders of Manhattan
Research common stock received a total of 83,620,271 shares of Manhattan common
stock, representing 80% of the total number of shares of Manhattan common stock
outstanding immediately after the effective time of the merger. Also as a result
of the merger, warrants to purchase 864,280 shares of Manhattan Research common
stock were converted into warrants to purchase 9,839,313 shares of Manhattan
common stock.
David M. Tanen serves as a member of the board of directors of both
Manhattan and Manhattan Research. He has served on the Manhattan board of
directors since January 28, 2002, and on Manhattan Research's board of directors
since its inception on August 6, 2001. In addition, Dr. Lindsay Rosenwald
beneficially owned approximately 28% of the outstanding pre-merger Manhattan
common stock as well as 14.2% of the outstanding pre-merger Manhattan Research
common stock.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(a) Financial Statements of Businesses Acquired.
The following financial statements of Manhattan Research are included in
this current report: (1) balance sheets as of September 30, 2002 and December
31, 2001; (2) statements of operations for the nine months ended September 30,
2002, for the period from August 6, 2001 (inception) to December 31, 2001 and
for the period from August 6, 2001 (inception) to September 30, 2002; (3)
statements of changes in stockholders' deficiency for the period from August 6,
2001 (inception) to September 30, 2002; (4) statements of cash flows for the
nine months ended September 30, 2002, for the period from August 6, 2001
(inception) to December 31, 2001, and for the period from August 6, 2001
(inception) to September 30, 2002; and (5) notes to financial statements as of
September 30, 2002 and December 31, 2001.
Financial statements of Manhattan Research for the year ended December 31,
2002 will be filed by an amendment to this current report within 60 days of the
filing of this current report.
(b) Pro Forma Financial Information
The following pro forma financial information is included in this current
report: (1) pro forma condensed combined balance sheet as of September 30, 2002
(unaudited); (2) pro forma condensed combined statement of operations for the
nine months ended September 30, 2002 (unaudited); (3) pro forma condensed
combined statement of operations
2
from August 6, 2001 to December 31, 2001; and (4) notes to unaudited pro forma
condensed combined financial statements.
(c) Exhibits.
2.1 Merger agreement dated as of December 17, 2002 between Atlantic
Technology Ventures, Inc., Manhattan Pharmaceuticals Acquisition Corp.
and Manhattan Pharmaceuticals, Inc.
23.1 Report of Weinberg & Company, P.A.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
Manhattan Pharmaceuticals, Inc. has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
Date: March 10, 2003 MANHATTAN PHARMACEUTICALS, INC.
By: /s/ Leonard Firestone
-------------------------------
Leonard Firestone
President and Chief Executive Officer
3
MANHATTAN PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
BALANCE SHEETS
ASSETS
September 30, December 31,
2002 2001
------------- -----------
CURRENT ASSETS
Cash $ 3,279 $ --
Deferred consulting expense 45,442 --
--------- ---------
Total Current Assets 48,721 --
--------- ---------
OTHER ASSETS
Deferred offering costs 8,706 --
Total Other Assets 8,706 --
--------- ---------
TOTAL ASSETS $ 57,427 $ --
========= =========
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
CURRENT LIABILITIES
Accounts payable $ 161,846 $ --
Accrued expenses 43,696 29,296
Note and interest payable 601,346 --
Due to stockholder 30,000 27,500
Due to affiliate 51,315 --
--------- ---------
Total Current Liabilities 888,203 56,796
--------- ---------
STOCKHOLDERS' DEFICIENCY
Common stock, $.001 par value, 10,000,000 shares authorized, 5,000,000
and 4,000,000 issued and outstanding in 2002 and 2001, respectively 5,000 4,000
Additional paid-in capital 60,589 --
Accumulated deficit during development stage (892,365) (56,796)
Subscription receivable (4,000) (4,000)
--------- ---------
Total Stockholders' Deficiency (830,776) (56,796)
--------- ---------
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY $ 57,427 $ --
========= =========
See accompanying notes to financial statements.
F-1
MANHATTAN PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF OPERATIONS
For the Period
from For the Period
For the Nine August 6, 2001 August 6, 2001
Months Ended (Inception) to (Inception) to
September 30, December 31, September 30,
2002 2001 2002
------------ -------------- --------------
REVENUE $ -- $ -- $ --
--------- --------- ---------
OPERATING EXPENSES
Consulting fees 217,885 27,736 245,621
Selling, general and administrative 186,250 1,560 187,810
Research and development 377,654 27,500 405,154
Salaries 41,667 -- 41,667
--------- --------- ---------
Total Operating Expenses 823,456 56,796 880,252
--------- --------- ---------
LOSS FROM OPERATIONS (823,456) (56,796) (880,252)
--------- --------- ---------
OTHER EXPENSE
Interest expense 12,113 -- 12,113
--------- --------- ---------
Total Other Expense 12,113 -- 12,113
--------- --------- ---------
NET LOSS $(835,569) $ (56,796) $(892,365)
========= ========= =========
See accompanying notes to financial statements.
F-2
MANHATTAN PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIENCY
FOR THE PERIOD FROM AUGUST 6, 2001 (INCEPTION) TO SEPTEMBER 30, 2002
Additional
Common Stock Paid-In Subscription Accumulated Total
Shares Amount Capital Receivable Deficit Equity
--------- ---------- ------------ ------------- ------------- ----------
Stock issued for subscription receivable 4,000,000 $ 4,000 $ -- $ (4,000) $ -- $ --
Net loss for the period from August 6, 2001
(inception) to December 31, 2001 -- -- -- -- (56,796) (56,796)
--------- --------- --------- --------- --------- ---------
Balance, December 31, 2001 4,000,000 4,000 -- (4,000) (56,796) (56,796)
Stock issued for licensing fees 1,000,000 1,000 -- -- -- 1,000
Stock options issued for services -- -- 60,589 -- -- 60,589
Net loss for the period from January 1, 2002
to September 30, 2002 -- -- -- -- (835,569) (835,569)
--------- --------- --------- --------- --------- ---------
BALANCE, SEPTEMBER 30, 2002 5,000,000 $ 5,000 $ 60,589 $ (4,000) $(892,365) $(830,776)
========= ========= ========= ========= ========= =========
See accompanying notes to financial statements.
F-3
MANHATTAN PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF CASH FLOWS
For the Period For the Period
from from
For the Nine August 6, 2001 August 6, 2001
Months Ended (Inception) to (Inception) to
September 30, December 31, September 30,
2002 2001 2002
-------------- -------------- -------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $(835,569) $ (56,796) $(892,365)
Adjustments to reconcile net loss to net cash (used in)
operating activities:
Expense portion of stock and options issued for services 16,147 -- 16,147
Changes in operating assets and liabilities:
(Increase) in:
Deferred offering costs (8,706) -- (8,706)
Increase in:
Accounts payable 161,846 -- 161,846
Accrued expenses 14,400 29,296 43,696
Due to affiliate 51,315 -- 51,315
Interest payable 1,346 -- 1,346
--------- --------- ---------
Net Cash Used In Operating Activities (599,221) (27,500) (626,721)
--------- --------- ---------
CASH FLOWS FROM INVESTING ACTIVITIES: -- -- --
--------- --------- ---------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from loans payable - related parties, net
of repayments 2,500 27,500 30,000
Proceeds from notes payable 600,000 -- 600,000
--------- --------- ---------
Net Cash Provided by Financing Activities 602,500 27,500 630,000
--------- --------- ---------
NET INCREASE IN CASH 3,279 -- 3,279
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD -- -- --
--------- --------- ---------
CASH AND CASH EQUIVALENTS - END OF PERIOD $ 3,279 $ -- $ 3,279
========= ========= =========
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest $ 10,767 $ -- $ 10,767
========= ========= =========
See accompanying notes to financial statements.
F-4
MANHATTAN PHARMACEUTICALS, INC.
(A Development Stage Company)
Notes to Financial Statements
NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING FOLICIES
(A) Nature of Operations
Manhattan Pharmaceuticals, Inc. (the "Company") incorporated on August 6,
2001 under the laws of Delaware under the name CT-3 Acquisition Corp., is
a privately-held, New York based development stage biopharmaceutical
company that holds an exclusive, world-wide license to certain
intellectual property (the "Property") owned by Oleoyl-estrone
Developments, SL ("OED") of Barcelona, Spain (the "University"). The
Company's first drug candidate, oleoyl-estrone ("OE"), is an orally
administered small molecule that has been shown in extensive pre-clinical
animal studies to cause significant weight loss without the need for
dietary modifications (See Notes 2 and 7).
(B) Use of Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those
estimates.
(C) Income Taxes
The Company accounts for income taxes under the Financial Accounting
Standards Board Statement of Financial Accounting Standards No. 109
"Accounting for Income Taxes" ("Statement 109"). Under Statement 109,
deferred tax assets and liabilities are recognized for the future tax
consequences attributable to differences between the financial statement
carrying amounts of existing assets and liabilities and their respective
tax bases. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those
temporary differences are expected to be recovered or settled. Under
Statement 109, the effect on deferred tax assets and liabilities of a
change in tax rates is recognized in income in the period that includes
the enactment date. There was no current or deferred income tax expense
(benefit) recorded for period from August 6, 2001 (inception) to December
31, 2001 and for the nine months ended September 30, 2002 because of the
Company's continued losses from operations. Any deferred tax asset
arising from the Company's available net operating loss carryforwards has
been offset by an equal valuation allowance.
(D) New Accounting Pronouncements
The Financial Accounting Standards Board has recently issued several new
Statements of Financial Accounting Standards.
Statement No. 141, "Business Combinations" supersedes APB Opinion 16 and
various related pronouncements. Pursuant to the new guidance in Statement
No. 141, all business combinations must be accounted for under the
purchase method of accounting; the pooling-of-interests method is no
longer permitted. SFAS 141 also establishes new rules concerning the
recognition of goodwill and other intangible assets arising in a purchase
business combination and requires disclosure of more information
concerning a business combination in the period in which it is completed.
This statement is generally effective for business combinations initiated
on or after July 1, 2001.
Statement No. 142, "Goodwill and Other Intangible Assets" supercedes APB
Opinion 17 and related interpretations. Statement No. 142 establishes new
rules on accounting for the acquisition of intangible assets not acquired
in a business combination and the manner in which goodwill and all other
intangibles should be accounted for subsequent to their initial
recognition in a business combination accounted for under SFAS No. 141.
Under SFAS No. 142, intangible assets should be recorded at fair value.
Intangible assets with finite useful lives should be amortized over such
period and those with indefinite lives should not be amortized. All
F-5
MANHATTAN PHARMACEUTICALS, INC.
(A Development Stage Company)
Notes to Financial Statements
intangible assets being amortized as well as those that are not, are both
subject to review for potential impairment under SFAS No. 121,
"Accounting for the Impairment of Long-Lived Assets and for Long-Lived
Assets to be Disposed of". SFAS No. 142 also requires that goodwill
arising in a business combination should not be amortized but is subject
to impairment testing at the reporting unit level to which the goodwill
was assigned to at the date of the business combination.
SFAS No. 142 is effective for fiscal years beginning after December 15,
2001 and must be applied as of the beginning of such year to all goodwill
and other intangible assets that have already been recorded in the
balance sheet as of the first day in which SFAS No. 142 is initially
applied, regardless of when such assets were acquired. Goodwill acquired
in a business combination whose acquisition date is on or after July 1,
2001, should not be amortized, but should be reviewed for impairment
pursuant to SFAS No. 121, even though SFAS No. 142 has not yet been
adopted. However, previously acquired goodwill should continue to be
amortized until SFAS No. 142 is first adopted.
Statement No. 143 "Accounting for Asset Retirement Obligations"
establishes standards for the initial measurement and subsequent
accounting for obligations associated with the sale, abandonment, or
other type of disposal of long-lived tangible assets arising from the
acquisition, construction, or development and/or normal operation of such
assets. SFAS No. 143 is effective for fiscal years beginning after June
15, 2002, with earlier application encouraged.
In August 2001, the FASB issued SFAS No. 144, "Accounting for the
Impairment or Disposal of Long-Lived Assets," which supersedes SFAS No.
121, "Accounting for the Impairment of Long-lived Assets and Long-lived
Assets to be Disposed of" and APB No. 30, "Reporting the Results of
Operations - Reporting the Effects of Disposal of a Segment of Business
and Extraordinary, Unusual and Infrequently Occurring Events and
Transactions." SFAS No. 144 established a single accounting model for
assets to be disposed of by sale whether previously held and used or
newly acquired. SFAS No. 144 retains the provision of APB No. 30 for
presentation of discontinued operations in the income statement but
broadens the presentation to include a component of an entity. SFAS No.
144 is effective for fiscal years beginning after December 15, 2001 and
the interim periods within.
In April 2002, the FASB issued SFAS 145, Rescission of FASB Statements
No. 4, 44, and 64, Amendment of FASB Statement No. 13, and Technical
Corrections. SFAS 145 rescinds the provisions of SFAS No. 4 that requires
companies to classify certain gains and losses from debt extinguishments
as extraordinary items, eliminates the provisions of SFAS No. 44
regarding transition to the Motor Carrier Act of 1980 and amends the
provisions of SFAS No. 13 to require that certain lease modifications be
treated as sale leaseback transactions. The provisions of SFAS 145
related to classification of debt extinguishments are effective for
fiscal years beginning after May 15, 2002. Earlier application is
encouraged. The Company does not believe the adoption of this standard
will have a material impact the financial statements.
In July 2002, the FASB issued SFAS No. 146, "Accounting for Restructuring
Costs." SFAS 146 applies to costs associated with an exit activity
(including restructuring) or with a disposal of long-lived assets. Those
activities can include eliminating or reducing product lines, terminating
employees and contracts and relocating plant facilities or personnel.
Under SFAS 146, the Company will record a liability for a cost associated
with an exit or disposal activity when that liability is incurred and can
be measured at fair value. SFAS 146 will require the Company to disclose
information about its exit and disposal activities, the related costs,
and changes in those costs in the notes to the interim and annual
financial statements that include the period in which an exit activity is
initiated and in any subsequent period until the activity is completed.
SFAS 146 is effective prospectively for exit or disposal activities
initiated after December 31, 2002, with earlier adoption encouraged.
Under SFAS 146, a company cannot restate its previously issued financial
statements and the new statement grandfathers the accounting for
liabilities that a company had previously recorded under Emerging Issues
Task Force Issue 94-3.
The Company believes that the adoption of these pronouncements will not
have a material impact on the Company's financial position or results of
operations.
F-6
MANHATTAN PHARMACEUTICALS, INC.
(A Development Stage Company)
Notes to Financial Statements
NOTE 2 RIGHTS TO INTELLECTUAL PROPERTY
The Company's exclusive right to OED's Property, in the aggregate, are of
material importance for the Company's survival. Protection for OED's
individual products extends for varying periods in accordance with the
date of grant and the legal life of patents in the various countries. The
protection afforded, which may also vary from country to country, depends
upon the type of patent and its scope of coverage. The Company is
financially responsible for all aspects of OED's inventions, including
legal and research and development expenses associated with the product
developments.
During the periods ended September 30, 2002 and December 31, 2001, the
Company capitalized approximately $236,303 and $25,000, respectively, in
legal fees, U.S. Patent office handling fees and other expenses that OED
incurred in relation to the patents and licensing fees (See Note 7).
Expenses incurred for research and development of the patents were
expensed in the period ended September 30, 2002.
The Intellectual Property Rights are being amortized over the lives of
the underlying patents, which generally are twenty years. Amortization
expense was not recorded for the period ended December 31, 2001.
Amortization expense related to patents for the period ended September
30, 2002 was approximately $263. No amortization has been recorded
related to the capitalized licensing costs that the Company has paid
under its licensing agreement with OED (See Note 7). Capitalized
licensing costs will be amortized when the licensing agreement generates
revenues from the underlying intellectual property rights.
The Company evaluates the recoverability of the Intellectual Property
Rights, where indicators of impairment are present, by reviewing current
and projected profitability or undiscounted cash flows of such assets.
Intangible assets that are subject to amortization are reviewed for
potential impairment whenever events or circumstances indicate that
carrying amounts may not be recoverable. Intangible assets not subject to
amortization are tested for impairment at least annually. For the period
ended September 30, 2002, the Company determined that, based on projected
profitability and estimated future cash flows, the carrying amount of the
Intellectual Property Rights, equals the fair value. Accordingly, no
impairment loss was required for the period ended September 30, 2002.
NOTE 3 NOTE PAYABLE
During the period ended September 30, 2002, the Company received $600,000
from an independent financial institution with an annual interest rate of
3.23%. During the period ended September 30, 2002, the Company paid
$10,767 and accrued $1,346 of the $12,113 total interest expense
incurred. The note is due in January 2003 and is secured by a
stockholder's personal investment account of $600,000. The note and
related interest payable are recorded in current liabilities in the
accompanying financial statements.
NOTE 4 DUE TO STOCKHOLDER
In order to provide operating funds for the Company, a stockholder (the
"Stockholder") loaned the Company $30,000 during September 2002. The loan
is payable on the earlier to occur of (a) one year from the date of
issuance or (b) a financing in which gross proceeds to the Company
exceeds $1,000,000. The loan bears interest at 5% and is unsecured. Since
the proceeds were received in late September 2002, no interest expense
has been recognized for this loan as of September 30, 2002 because the
Company deems it to be immaterial.
As discussed in Note 10, the Company received an additional $80,000 from
the Stockholder during October 2002 as additional operating funds. The
total proceeds from the Stockholder since inception is $110,000 (See Note
10).
NOTE 5 DUE TO AFFILIATE
During the period ended September 30, 2002, an affiliate, owned by the
Stockholder as defined in Note 4, paid
F-7
MANHATTAN PHARMACEUTICALS, INC.
(A Development Stage Company)
Notes to Financial Statements
paid $6,315 for deferred offering expenses on behalf of the Company. The
Company also owes $45,000 at September 30, 2002 for office space rental
expense to the affiliate. These expenses are included in selling, general
and administrative expense on the accompanying financial statements.
These non-interest bearing payables are due on demand and unsecured.
NOTE 6 STOCKHOLDERS' DEFICIENCY
The Company accounts for equity based compensation in accordance with
Statement of Financial Accounting Standards No. 123, "Accounting for
Stock-Based Compensation". The standard requires the Company to adopt the
"fair value" method with respect to equity-based compensation of
consultants and other non-employees. For financial statement disclosure
purposes, the fair market value of each stock option granted during the
period ended September 30, 2002 was estimated on the date of grant using
the Black-Scholes Pricing Model in accordance with FASB No. 123 using the
following weighted average assumptions: expected dividend yield 0%,
risk-free interest rate of 3.21%, volatility of 0% and expected term of
five years.
The Company issued a total of 40,000 options to four consultants to
purchase 40,000 shares of the Company's common stock at an exercise price
of $.01 during August 2002. The fair value of the option issuances was
estimated, using the Black-Scholes Pricing Model as described in the
previous paragraph, at $60,589. The option issuances were granted as
payment in full for four one-year consulting contracts, which all
terminate in August 2003. Therefore the Company has expensed $15,147 as
consulting fee expense in the accompanying statement of operations and
has deferred $45,442 over the remaining lives of the contracts, which is
presented as deferred consulting expense on the balance sheet of the
accompanying financial statements.
There were no options exercised during the period ended September 30,
2002.
The Company did not adopt the fair value method, in accordance with SFAS
123, with respect to employee stock options. The Company accounts for
employee stock options under the "intrinsic value" method in accordance
with APB 25. For the period from August 6, 2001 (inception) through
September 30, 2002, the Company did not issue options to employees.
Therefore, there was no financial statement impact for employee option
issuances for the periods presented.
The Company issued 4,000,000 shares of common stock to thirty-eight
investors during December 2001 for a subscription receivable of $4,000.
In connection with the subscription receivable, the Company entered into
thirty-eight note receivable agreements with the respective investors,
which all mature during 2002. (See Note 10 for discussion of subsequent
proceeds from subscriptions receivable). During February 2002, the
Company issued 1,000,000 shares of common stock to OED related to the
license agreement discussed in Note 7 and capitalized the full amount as
licensing fees.
NOTE 7 LICENSE AND CONSULTING AGREEMENTS
On February 15, 2002, the company entered into a License Agreement (the
"Agreement") with OED. Under the terms of the Agreement, OED grants to
the Company a worldwide license to make, use, lease and sell the licensed
products as the Company's sees fit. OED also grants the right to the
Company to sublicense to third parties the Property or aspects of the
Property with prior written consent of OED. OED retains an irrevocable,
non-exclusive, royalty-free right to use the Property solely for its
internal, non-commercial use. The Agreement will terminate on (i) the
date that the Company files a petition for bankruptcy, (ii) within thirty
days notice that the University's research agreement ceases to be in full
force, (iii) within sixty days notice by either party for due reason as
specified in the Agreement or (iv) the date for the last patent to expire
under the Agreement.
Under the Agreement, the Company agreed to pay to OED certain equity and
milestone licensing fees, which are being capitalized as they are paid in
the accompanying financial statements. As of September 30, 2002 and 2001
the Company paid $175,000 and $25,000, respectively in licensing fees
which is included in the balance
F-8
MANHATTAN PHARMACEUTICALS, INC.
(A Development Stage Company)
Notes to Financial Statements
sheet as intellectual property rights (See Note 2).
In relation to the Agreement, the Company entered into a consulting
agreement with Oleoyl-estrone Developments, SL ("OED"). The agreement
became effective during February 2002, at a fee of $6,250 per month, and
will terminate when the license agreement terminates. The fees associated
with the consulting agreement are expensed in the accompanying financial
statements. OED agreed to serve as a member of the Company's Scientific
Advisory Board and to render consultative and advisory services to the
Company. Such services include research, development and clinical testing
of the Company's technology as well as the reporting of the findings of
such tests, assistance in filing of patents and oversight and direction
of efforts in regards to personnel for clinical development.
NOTE 8 PRIVATE PLACEMENT
During the period ended September 30, 2002, the Company commenced a
private placement share offering wherein it offered to accredited
investors a minimum amount of 312,500 shares and a maximum amount of
937,500 shares of common stock. The purchase price per share was $1.60
per share with an individual minimum investment of $50,000, although the
Company may accept, at their discretion, subscriptions for lesser
amounts. As of September 30, 2002, the Company had not closed on any
proceeds related to the offering. In connection with this private
placement offering the Company incurred offering costs of $8,706 which
have been deferred.
NOTE 9 GOING CONCERN
The Company's financial statements have been prepared on a going concern
basis which contemplated the realization of assets and the settlement of
liabilities and commitments in the normal course of business. The Company
has a net loss from operations of $630,325 since inception, a negative
cash flow from operating activities of $365,418 since inception, a
working capital deficiency of $839,482 and a stockholders' deficiency of
$568,736. The Company's working capital deficiency may not enable it to
meet such objectives as presently structured. The financial statements do
not include any adjustments that might result from the outcome of this
uncertainty.
The ability of the Company to continue as a going concern is dependent on
the Company's ability to obtain additional financing and achieve
profitable operations. Management believes that actions presently taken
to obtain additional financing and its business plan to achieve
profitable operations will provide the opportunity for the Company to
continue as a going concern.
NOTE 10 SUBSEQUENT EVENTS
During October 2002, the Company received an additional $80,000 of
operating funds from the Stockholder referred to in Note 4. The loans are
unsecured and bear interest at 5%.
During October 2002, the Company received proceeds of $4,000 as payment
in full of the $4,000 subscription receivable.
F-9
INTRODUCTION TO THE UNAUDITED PRO FORMA
CONDENSED COMBINED FINANCIAL STATEMENTS
Atlantic Technology Ventures, Inc. recently signed a merger agreement with
Manhattan Pharmaceuticals, Inc. providing for the merger of a wholly owned
subsidiary of Atlantic into Manhattan. If the merger is consummated,
shareholders of Manhattan will be issued approximately 92,647,100 shares of
Atlantic which represents 80% of Atlantic's post-merger outstanding capital
stock. We anticipate that the merger will close in the first quarter of 2003.
The merger will be recorded as a reverse acquisition since the Manhattan
stockholders become the controlling stockholders of Atlantic. Based on the
recent thirty-day average price of Atlantic's common stock of $0.12, the
preliminary estimate of the total purchase price is approximately $2,979,413. On
completion of a valuation, it is expected that the combined company will record
intangible assets (patents and licenses) for substantially all of the purchase
price.
The Unaudited Pro Forma Condensed Combined Statements of Operations
combine the historical consolidated statements of operations of Atlantic and
Manhattan. The Unaudited Pro Forma Condensed Combined Balance Sheet combines the
historical consolidated balance sheet of Atlantic and the historical
consolidated balance sheet of Manhattan, giving effect to the merger as if it
had been consummated on September 30, 2002.
You should read this information in conjunction with the:
o accompanying notes to the Unaudited Pro Forma Condensed Combined
Financial Statements;
o separate historical unaudited financial statements of Atlantic as of
and for the nine months ended September 30, 2002 and for the period
from July 13, 1993 (inception) to September 30, 2002 included in
Atlantic's Quarterly Report on Form 10-QSB for the nine month period
ended September 30, 2002, which is included in this document;
o separate historical financial statements of Manhattan as of and for
the nine months ended September 30, 2002 and for the period ended
December 31, 2001; and
o separate historical financial statements of Atlantic for the year
ended December 31, 2001 included in Atlantic's Annual Report on Form
10-KSB for the year ended December 31, 2001, and for the period from
July 13, 1993 (inception) to December 31, 2001, which is incorporated
by reference into this document.
We present the unaudited pro forma condensed combined financial
information for informational purposes only. The pro forma information is not
necessarily indicative of what our financial position or results of operations
actually would have been had we completed the merger on September 30, 2002. In
addition, the unaudited pro forma condensed combined financial information does
not purport to project the future financial position or operating results of the
combined company.
We prepared the unaudited pro forma condensed combined financial
information using the purchase method of accounting with Manhattan treated as
the acquirer. Accordingly, Manhattan's cost to acquire Atlantic will be
allocated to the assets acquired and liabilities assumed based upon their
estimated fair values as of the date of acquisition. The allocation is dependent
upon certain valuations and other studies that have not progressed to a stage
where there is sufficient information to make a definitive allocation.
Accordingly, the purchase price allocation pro forma adjustments are preliminary
and have been made solely for the purpose of providing unaudited pro forma
condensed combined financial information.
F-10
UNAUDITED PRO FORMA CONDENSED
COMBINED BALANCE SHEET
(DEVELOPMENT STAGE COMPANIES)
As of September 30, 2002
Atlantic Manhattan
Technology Pharmaceuticals Pro forma Pro forma
Ventures, Inc. Inc. Adjustments Combined
Assets ------------ --------------- ----------- ---------
Current assets:
Cash and cash equivalents $ 375,845 3,279 (200,000) (e) 179,124
Prepaid expenses 81,614 -- -- 81,614
Deferred consulting expense -- 45,442 -- 45,442
------------ ------------ ------------ ---------
Total current assets 457,459 48,721 (200,000) 306,180
Property and equipment, net 70,237 -- (55,000) (f) 15,237
Intangible assets -- -- 2,979,413 2,979,413
Other assets 19,938 8,706 -- 28,644
------------ ------------ ------------ ---------
Total assets $ 547,634 57,427 (2,724,413) 3,329,474
============ ============ ============ =========
Liabilities and Stockholders' Equity (Deficiency)
Current liabilities:
Accounts payable and accrued
expenses $ 503,945 205,542 -- 709,487
Note and interest payable -- 601,346 -- 601,346
Due to stockholder -- 30,000 -- 30,000
Due to affiliate -- 51,315 -- 51,315
------------ ------------ ------------ ---------
Total current liabilities $ 503,945 888,203 -- 1,392,148
Stockholders' equity (deficiency):
Preferred stock 379 -- (379) (a) --
Preferred warrants 520,263 -- (520,263) (a) --
Common Stock 16,990 5,000 93,819 (b) 115,809
Additional paid-in capital 27,411,259 60,589 (24,753,966) (g) 2,717,882
Deficit accumulated during (27,904,660) (892,365) 27,904,660 (c) (892,365)
development stage
------------ ------------ ------------ ---------
44,231 (826,776) 2,723,871 1,941,326
Less common stock subscriptions
receivable (218) (4,000) 218 (d) (4,000)
Less treasury stock, at cost (324) -- 324 (d) --
------------ ------------ ------------ ---------
Total stockholders'
equity (deficiency) 43,689 (830,776) 2,724,413 1,937,326
------------ ------------ ------------ ---------
Total liabilities and
stockholders' equity (deficiency) $ 547,634 57,427 2,724,413 3,329,474
============ ============ ============ =========
See accompanying notes to unaudited pro forma condensed combined financial
statements.
F-11
UNAUDITED PRO FORMA CONDENSED
COMBINED STATEMENT OF OPERATIONS
(DEVELOPMENT STAGE COMPANIES)
For the Nine Months Ended September 30, 2002
Atlantic Manhattan
Technology Pharmaceuticals, Pro forma Pro forma
Ventures, Inc. Inc. Adjustments Combined
--------------- --------------- ------------ -----------
License Revenues: 500,000 $ -- $ -- $ --
------------ ------------ ------------ ------------
Costs and expenses:
Research and development 467,153 377,654 -- 844,807
Amortization of intangibles -- -- 223,456 (h) 223,456
Consulting fees -- 217,885 -- 217,885
General and administrative 1,219,356 227,917 -- 1,447,273
------------ ------------ ------------ ------------
Total operating expenses 1,686,509 823,456 223,456 2,733,421
------------ ------------ ------------ ------------
Operating loss (1,686,509) (823,456) (223,456) (2,733,421)
Other (income) expense:
Interest and other (income) (10,255) 12,113 -- 1,858
expense
------------ ------------ ------------ ------------
Total other (income) expense (10,255) 12,113 -- 1,858
------------ ------------ ------------ ------------
Net loss (1,176,254) $ (835,569) $ (223,456) (2,735,279)
============ ============ ============ ============
Preferred stock dividend issued in
preferred shares 65,760 -- -- 65,760
------------ ------------ ------------ ------------
Net loss applicable to common (1,242,014) $ (835,569) $ (223,456) (2,801,039)
shares
============ ============ ============ ============
Net loss per common share:
Basic and diluted (0.02)
============
Weighted average shares of common stock outstanding:
Basic and diluted 115,808,875
============
See accompanying notes to unaudited pro forma condensed combined financial
statements.
F-12
UNAUDITED PRO FORMA CONDENSED
COMBINED STATEMENT OF OPERATIONS
(DEVELOPMENT STAGE COMPANIES)
For the Year Ended December 31, 2002
Manhattan
Pharmaceuticals,
Inc.
Atlantic Technology For the period from
Ventures, Inc. August 6, 2001
For the year ended (inception) to Pro forma Pro forma
December 31, 2001 December 31, 2001 Adjustments Combined
-------------------- ------------------- ----------- ----------
Revenues:
Development revenue $ 2,461,922 $ -- $ -- 2,461,922
Grant revenue 250,000 -- -- 250,000
----------- ----------- ----------- -----------
Total revenues $ 2,711,922 $ -- $ -- $ 2,711,922
----------- ----------- ----------- -----------
Costs and expenses:
Cost of development revenue 2,082,568 -- -- 2,082,568
Research and development 886,716 27,500 -- 914,216
Amortization of intangibles -- -- 297,941 (h) 297,941
Consulting Fees -- 27,736 -- 27,736
General and administrative 2,771,407 1,560 -- 2,772,967
Compensation expense (benefit) relating to stock
warrants (general and administrative), net 78,611 -- -- 78,611
----------- ----------- ----------- -----------
Total operating expenses 5,819,302 56,796 297,941 6,174,039
----------- ----------- ----------- -----------
Operating loss (3,107,380) (56,796) (297,941) (3,462,117)
Other (income) expense:
Interest and other income (42,010) -- -- (42,010)
Gain on sale of Optex assets (2,569,451) -- -- (2,569,451)
Loss on sale of Gemini assets 334,408 -- -- 334,408
Equity in loss of affiliate 67,344 -- -- 67,344
Distribution to minority shareholders 837,274 -- -- 837,274
----------- ----------- ----------- -----------
Total other income (1,372,435) -- -- (1,372,435)
----------- ----------- ----------- -----------
Net loss $(1,734,945) $ (56,796) $ (297,941) (2,089,682)
=========== =========== =========== ===========
Imputed convertible preferred stock dividend 600,000 -- -- 600,000
Dividend paid upon repurchase of Series B 167,127 -- -- 167,127
Preferred stock dividend issued in
preferred shares 107,449 -- -- 107,449
----------- ----------- ----------- -----------
Net loss applicable to common shares $(2,609,521) $ (56,796) $ (297,941) (2,964,258)
=========== =========== =========== ===========
Net loss per common share:
Basic and diluted (0.03)
===========
Weighted average shares of common stock outstanding:
Basic and diluted 115,808,875
===========
See accompanying notes to unaudited pro forma condensed combined financial
statements.
F-13
NOTES TO
UNAUDITED PRO FORMA CONDENSED
COMBINED FINANCIAL STATEMENTS
(DEVELOPMENT STAGE COMPANIES)
(1) DESCRIPTION OF TRANSACTION AND BASIS OF PRESENTATION
The merger is expected to be completed in the first quarter of 2003. The
Unaudited Pro Forma Condensed Combined Statements of Operations combine the
historical consolidated statements of operations of Atlantic, a public company,
and Manhattan. The merger agreement, dated December 17, 2002, provides for the
stockholders of Manhattan exchanged all of their shares of Manhattan stock for
92,647,100 shares of common stock of Atlantic. The merger, which is subject to
shareholder approval, will be recorded as a reverse acquisition since the
Manhattan stockholders become the controlling stockholders of Atlantic. Based on
the recent thirty-day average price of Atlantic's common stock of $0.12, the
preliminary estimate of the total purchase price approximates $2,979,413. Upon
completion of a valuation, it is expected that the combined company will record
intangible assets (patents and licenses) for substantially all of the purchase
price.
We recognize that if the final valuation, which is expected to be
completed within three to six weeks from the completion of the merger, derives
different amounts from our preliminary estimate, we will adjust the combined
condensed financial statements.
The merger will be accounted for as a purchase by Manhattan under
accounting principles generally accepted in the United States of America. Under
the purchase method of accounting, the assets and liabilities of Atlantic will
be recorded as of the acquisition date, at their respective fair values, and
combined with those of Manhattan. The reported financial condition and results
of operations of Manhattan after completion of the merger will reflect these
values, but will not be restated retroactively to reflect the historical
financial position or results of operations of Atlantic. The merger is subject
to customary closing conditions, including regulatory approvals, as well as
approval by Atlantic and Manhattan shareholders of certain merger-related
proposals.
(2) pro forma adjustments
(a) To reflect conversion of preferred stock and preferred warrants to
4,044,634 shares of common stock.
(b) To reflect issuance of 92,647,100 shares to the common shareholders of
Manhattan and the conversion of Atlantic's preferred stock and preferred
warrants and the exchange of certain common stock warrants in connection
with the merger.
(c) To eliminate deficit accumulated during development stage of Atlantic and
to record (1) the estimated in-process research and development charge
based on the preliminary estimated purchase price of Atlantic and (2)
estimated expenses associated with the merger.
(d) To eliminate subscriptions receivable and treasury stock of Atlantic.
(e) To reflect estimated merger expenses.
(f) To reflect the fair value of property and equipment.
(g) To eliminate historical paid in capital of Atlantic and to reflect issuance
of new common shares in connection with the merger.
(h) To record amortization expense of intangible assets (patents and licenses)
assuming a weighted average ten year life.
F-14
Exhibit 2.1
AGREEMENT AND PLAN OF MERGER
This Agreement and Plan of Merger (this "Agreement") is entered into as of
December 17, 2002, by and among Manhattan Pharmaceuticals, Inc., a company duly
organized and existing under the laws of the State of Delaware, having a place
of business located at 787 Seventh Avenue, 48th Floor, New York, New York 10019
("Manhattan"), Atlantic Technology Ventures, Inc., a company duly organized and
existing under the laws of the State of Delaware, having a place of business
located at 350 Fifth Avenue, Suite 5507, New York, New York 10118 ("Atlantic"),
and Manhattan Pharmaceuticals Acquisition Corp., a company duly organized and
existing under the laws of the State of Delaware, having a place of business
located at 350 Fifth Avenue, Suite 5507 New York, New York 10118 (hereinafter
referred to "MPAC").
W I T N E S S E T H
WHEREAS, the Boards of Directors of Manhattan, Atlantic and MPAC have
determined that it is in the best interests of such corporations and their
respective stockholders to consummate the merger of MPAC with and into Manhattan
with Manhattan as the surviving corporation (the "Merger");
WHEREAS, Atlantic, as the sole stockholder of MPAC, has approved this
Agreement, the Merger and the transactions contemplated by this Agreement
pursuant to action taken by written consent in accordance with the requirements
of the Delaware General Corporation Law ("DGCL") and the Bylaws of MPAC;
WHEREAS, pursuant to the Merger, among other things, the outstanding
shares of common stock of Manhattan shall be converted into the right to receive
upon Closing (as hereinafter defined) and thereafter, the Merger Consideration
(as hereinafter defined);
WHEREAS, the parties to this Agreement intend to adopt this Agreement as a
plan of reorganization within the meaning of Section 368(a) of the Internal
Revenue Code of 1986, as amended (the "Code") and the regulations promulgated
thereunder, and intend that the Merger and the transactions contemplated by this
Agreement be undertaken pursuant to that plan; and
WHEREAS, the parties to this Agreement intend that the Merger qualify as a
"reorganization," within the meaning of Section 368(a) of the Code, and that
Atlantic, MPAC and Manhattan will each be a "party to a reorganization," within
the meaning of Section 368(b) of the Code, with respect to the Merger.
NOW, THEREFORE, in consideration of the representations, warranties and
covenants contained herein, the parties hereto agree as follows:
1
ARTICLE I
DEFINITIONS
As used herein, the following terms shall have the following meanings
(such meaning to be equally applicable to both the singular and plural forms of
the terms defined):
"Affiliate" has the meaning as defined in Rule 12b-2 promulgated under the
Exchange Act, as such regulation is in effect on the date hereof.
"Atlantic Common Stock" shall mean the common stock, par value $.001 per
share, of Atlantic.
"Atlantic 10-K Reports" shall have the meaning ascribed thereto in Section
4.4.
"Atlantic 10-Q Reports" shall have the meaning ascribed thereto in Section
4.4.
"Atlantic Proposals" has the meaning ascribed thereto in Section 6.9.
"Certificate of Merger" shall mean the certificate of merger in
substantially the form attached hereto as Exhibit A.
"Code" has the meaning ascribed thereto in the preambles to this
Agreement.
"Copyrights" has the meaning ascribed thereto in Section 3.20(a).
"Delaware General Corporation Law" or "DGCL" shall mean Title 8, Chapter 1
of the Delaware Code, as amended.
"Effective Date" shall have the meaning as set forth in Section 2.1(e)
hereof.
"Effective Time" shall have the meaning ascribed thereto in Section 2.1(e)
hereof.
"ERISA" means the Employee Retirement Income Security Act of 1974 or any
successor law and the regulations thereunder.
"Exchange Act" shall mean the Securities Exchange Act of 1934, as amended.
"Exchange Ratio" means the quotient resulting from dividing (A) four (4)
times the number of shares of Atlantic Common Stock outstanding immediately
prior to the Effective Time, by (B) the number of shares of Manhattan Common
Stock outstanding immediately prior to the Effective Time.
"GAAP" shall mean United States generally accepted accounting principles
as in effect from time to time.
"Intellectual Property" has the meaning ascribed thereto in Section
3.20(a).
2
"Know-How" has the meaning ascribed thereto in Section 3.20(a).
"Knowledge" means, with respect to an individual, that such individual is
actually aware of a particular fact or other matter, with no obligation to
conduct any inquiry or other investigation to determine the accuracy of such
fact or other matter. A person other than an individual shall be deemed to have
Knowledge of a particular fact or other matter if the officers, directors or
other management personnel of such person had Knowledge of such fact or other
matter.
"Manhattan Common Stock" means the common stock, par value $.001, of
Manhattan.
"Material Adverse Effect" shall, with respect to an entity, mean a
material adverse effect on the business, operations, results of operations or
financial condition of such entity on a consolidated basis.
"Merger" shall have the meaning ascribed thereto in the preambles of this
Agreement.
"Merger Consideration" means the shares of Atlantic Common Stock issuable
in connection with the Merger to the holders of Manhattan Common Stock based on
the Exchange Ratio.
"Patents" has the meaning ascribed thereto in Section 3.20(a).
"Person" means any individual, corporation (including any non-profit
corporation), general or limited partnership, limited liability company, joint
venture, estate, trust, association, organization, labor union, governmental
authority or other entity.
"Proxy Statement" shall have the meaning ascribed thereto in Section 6.4.
"Requisite Manhattan Stockholder Vote" shall have the meaning ascribed
thereto in Section 3.2.
"Requisite Atlantic Stockholder Votes" shall have the meaning ascribed
thereto in Section 4.2.
"SEC" shall mean the United States Securities and Exchange Commission.
"Securities Act" shall mean the Securities Act of 1933, as amended.
"Subsidiary" shall, with respect to any entity, mean each corporation in
which such entity owns directly or indirectly fifty percent (50%) or more of the
voting securities of such corporation and shall, unless otherwise indicated, be
deemed to refer to both direct and indirect subsidiaries of such entity.
"Surviving Company" shall have the meaning ascribed thereto in Article II.
3
"Tax or Taxes" shall mean any federal, state, local or foreign income,
gross receipts, license, payroll, employment, excise, severance, stamp,
occupation, premium, property or windfall profits taxes, environmental taxes,
customs duties, capital stock, franchise, employees' income withholding, foreign
or domestic withholding, social security, unemployment, disability, workers'
compensation, employment-related insurance, real property, personal property,
sales, use, transfer, value added, alternative or add-on minimum or other
governmental tax, fee, assessment or charge of any kind whatsoever including any
interest, penalties or additions to any Tax or additional amounts in respect of
the foregoing.
"Trademarks" has the meaning ascribed thereto in Section 3.20(a).
ARTICLE II
MERGER
Subject to the satisfaction or waiver of the conditions set forth in
Article VII, at the Effective Time, (i) MPAC will merge with and into Manhattan,
and (ii) Manhattan will become a wholly-owned subsidiary of Atlantic. The term
"Surviving Company" as used herein shall mean Manhattan, as a wholly-owned
subsidiary of Atlantic after giving effect to the Merger. The Merger will be
effected pursuant to the Certificate of Merger in accordance with the provisions
of, and with the effect provided in, Section 251 of the DGCL.
2.1 Effects of Merger.
(a) From and after the Effective Time and until further amended in
accordance with law, (i) the Certificate of Incorporation of Manhattan as in
effect immediately prior to the Effective Time shall be the Certificate of
Incorporation of the Surviving Company, and (ii) the Bylaws of Manhattan as in
effect immediately prior to the Effective Time shall be the Bylaws of the
Surviving Company.
(b) Atlantic, Manhattan and MPAC, respectively, shall each use its
best efforts to take all such action as may be necessary or appropriate to
effectuate the Merger in accordance with the DGCL at the Effective Time. If at
any time after the Effective Time, any further action is necessary or desirable
to carry out the purposes of this Agreement and to vest the Surviving Company
with full right, title and possession to all properties, rights, privileges,
immunities, powers and franchises of either Manhattan or MPAC, the officers of
the Surviving Company are fully authorized in the name of Atlantic, Manhattan
and MPAC or otherwise to take, and shall take, all such lawful and necessary
action.
(c) Subject to the provisions of Articles VII and VIII hereof, the
closing (the "Closing") of the transactions contemplated hereby shall take place
at such location, on such date (the "Closing Date") and at such time as
Manhattan and Atlantic mutually agree at the earliest practicable time after the
satisfaction or waiver of the conditions in Article VII, but in no event later
than ten (10) business days after all such conditions have been satisfied or
waived, or on such other date as may be mutually agreed by the parties hereto.
On the Closing Date, to effect the Merger, the parties hereto will cause the
Certificate of Merger to be filed with the Delaware Secretary of State in
accordance with the DGCL. The Merger shall be effective when
4
the Certificate of Merger is filed with the Delaware Secretary of State (the
"Effective Time"). As used herein, the term "Effective Date" shall mean the date
on which the Certificate of Merger is filed with the Delaware Secretary of
State.
2.2 Effect on Manhattan Capital Stock and MPAC Capital Stock. To
effectuate the Merger, and subject to the terms and conditions of this
Agreement, at the Effective Time:
(a) Each issued and outstanding share of Manhattan Common Stock
immediately prior to the Effective Time (other than shares to be extinguished
pursuant to this Section 2.2 and Dissenting Shares as defined in Section 2.5
below) shall be converted into and exchangeable for such number of fully paid
and non-assessable shares of Atlantic Common Stock equal to the Exchange Ratio,
and Atlantic shall issue to each holder of Manhattan Common Stock (other than
holders of shares extinguished pursuant to this Section 2.2 and Dissenting
Shares) the number of shares of Atlantic Common Stock equal to the number of
shares of Manhattan Common Stock held by such stockholder multiplied by the
Exchange Ratio, rounded to the nearest whole share;
(b) All shares of Manhattan Common Stock held at the Effective Time
by Manhattan as treasury stock will be canceled and no payment will be made with
respect to those shares;
(c) All outstanding options and warrants to purchase shares of
Manhattan Common Stock outstanding immediately prior to the Effective Time shall
convert to the right to purchase the same number of shares of Atlantic Common
Stock based on the Exchange Ratio as the holder thereof would have been entitled
to receive if such option or warrant had been exercised immediately prior to the
Effective Time, except that any fractional shares of Atlantic Common Stock
subject to any such converted option or warrant must be rounded to the nearest
share; and the exercise price per share of Atlantic Common Stock under each such
converted option or warrant will be equal to the quotient obtained by dividing
the exercise price per share of Manhattan Common Stock under each outstanding
Manhattan option or warrant by the Exchange Ratio, except that the exercise
price under each converted option or warrant must be rounded to the nearest
cent;
(d) Each share of Manhattan Common Stock issued and outstanding
immediately prior to the Effective Time and owned by MPAC or Atlantic, if any,
shall be cancelled and extinguished without any conversion thereof and no
payment shall be made with respect thereto; and
(e) All issued and outstanding shares of common stock, $0.01 par
value per share, of MPAC held by Atlantic immediately prior to the Effective
Time will be converted into and become one validly issued, fully paid and
nonassessable share of common stock of the Surviving Company.
5
2.3 Rights of Holders of Manhattan Capital Stock.
(a) On and after the Effective Date and until surrendered for
exchange, each outstanding stock certificate that immediately prior to the
Effective Date represented shares of Manhattan Common Stock (except Dissenting
Shares and shares cancelled or extinguished pursuant to Section 2.2) shall be
deemed for all purposes, to evidence ownership of and to represent the number of
whole shares of Atlantic Common Stock into which such shares of Manhattan Common
Stock shall have been converted pursuant to Section 2.2(a) above. The record
holder of each such outstanding certificate representing shares of Manhattan
Common Stock, shall, after the Effective Date, be entitled to vote the shares of
Atlantic Common Stock into which such shares of Manhattan Common Stock shall
have been converted on any matters on which the holders of record of the
Atlantic Common Stock, as of any date subsequent to the Effective Date, shall be
entitled to vote. In any matters relating to such certificates of Manhattan
Common Stock, Atlantic may rely conclusively upon the record of stockholders
maintained by Manhattan containing the names and addresses of the holders of
record of Manhattan Common Stock on the Effective Date.
(b) On and after the Effective Date, Atlantic shall reserve a
sufficient number of authorized but unissued shares of Atlantic Common Stock for
issuance in connection with (i) the conversion of Manhattan Common Stock into
Atlantic Common Stock and (ii) the exercise of all options and warrants to
purchase shares of Manhattan Common Stock outstanding immediately prior to the
Effective Time.
2.4 Procedure for Exchange of Manhattan Common Stock.
(a) After the Effective Time, holders of certificates theretofore
evidencing outstanding shares of Manhattan Common Stock (except Dissenting
Shares and shares cancelled or extinguished pursuant to Section 2.2), upon
surrender of such certificates to the registrar or transfer agent for Atlantic
Common Stock, shall be entitled to receive certificates representing the number
of whole shares of Atlantic Common Stock into which shares of Manhattan Common
Stock theretofore represented by the certificates so surrendered shall have been
converted as provided in Section 2.2(a) hereof. Atlantic shall not be obligated
to deliver the Merger Consideration to which any former holder of shares of
Manhattan Common Stock is entitled until such holder surrenders the certificate
or certificates representing such shares. Upon surrender, each certificate
evidencing Manhattan Common Stock shall be canceled. If there is a transfer of
Manhattan Common Stock ownership which is not registered in the transfer records
of Manhattan, a certificate representing the proper number of shares of Atlantic
Common Stock may be issued to a person other than the person in whose name the
certificate so surrendered is registered if: (x) upon presentation to the
Secretary of Atlantic, such certificate shall be properly endorsed or otherwise
be in proper form for transfer, (y) the person requesting such payment shall pay
any transfer or other taxes required by reason of the issuance of shares of
Atlantic Common Stock to a person other than the registered holder of such
certificate or establish to the reasonable satisfaction of Atlantic that such
tax has been paid or is not applicable, and (z) the issuance of such Atlantic
Common Stock shall not, in the sole discretion of Atlantic, violate the
requirements of the Regulation D "safe harbor" of the Securities Act with
respect to the private placement of Atlantic Common Stock that will result from
the Merger.
6
(b) All shares of Atlantic Common Stock issued upon the surrender
for exchange of Manhattan Common Stock in accordance with the above terms and
conditions shall be deemed to have been issued and paid in full satisfaction of
all rights pertaining to such shares of Manhattan Common Stock.
(c) No holder surrendering a certificate representing shares of
Manhattan Common Stock will be issued in exchange a certificate representing
other than a whole number of shares of Atlantic Common Stock.
(d) Any shares of Atlantic Common Stock issued in the Merger will
not be transferable except (1) pursuant to an effective registration statement
under the Securities Act or (2) upon receipt by Atlantic of a written opinion of
counsel reasonably satisfactory to Atlantic to the effect that the proposed
transfer is exempt from the registration requirements of the Securities Act and
relevant state securities laws. Restrictive legends must be placed on all
certificates representing shares of Atlantic Common Stock issued in the Merger,
substantially as follows:
"THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO
RESTRICTIONS ON TRANSFER AND CERTAIN OTHER CONDITIONS.
NO TRANSFER, SALE, ASSIGNMENT, PLEDGE, HYPOTHECATION OR OTHER DISPOSITION
OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY BE MADE EXCEPT (A)
PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT
OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS IN EFFECT THEREUNDER
AND ALL APPLICABLE STATE SECURITIES OR "BLUE SKY" LAWS (SUCH FEDERAL AND
STATE LAWS, THE "SECURITIES LAWS") OR (B) IF ATLANTIC TECHNOLOGY VENTURES,
INC. HAS BEEN FURNISHED WITH AN OPINION OF COUNSEL FOR THE HOLDER, WHICH
OPINION AND COUNSEL SHALL BE REASONABLY SATISFACTORY TO ATLANTIC
TECHNOLOGY VENTURES, INC., TO THE EFFECT THAT SUCH TRANSFER, SALE,
ASSIGNMENT, PLEDGE, HYPOTHECATION OR OTHER DISPOSITION IS EXEMPT FROM THE
PROVISIONS OF THE SECURITIES LAWS."
(e) In the event any certificate for Manhattan Common Stock shall
have been lost, stolen or destroyed, Atlantic shall issue and pay in exchange
for such lost, stolen or destroyed certificate, upon the making of an affidavit
of that fact by the holder thereof, such shares of the Atlantic Common Stock and
cash for fractional shares, if any, as may be required pursuant to this
Agreement; provided, however, that Atlantic, in its discretion and as a
condition precedent to the issuance and payment thereof, may require the owner
of such lost, stolen or destroyed certificate to deliver a bond in such sum as
it may direct as indemnity against any claim that may be made against Atlantic
or any other party with respect to the certificate alleged to have been lost,
stolen or destroyed.
2.5 Dissenting Shares.
(a) Shares of capital stock of Manhattan held by stockholders of
Manhattan who have properly exercised and preserved appraisal rights with
respect to those shares in
7
accordance with Section 262 of the DGCL ("Dissenting Shares") shall not be
converted into or represent a right to receive shares of Atlantic Common Stock
pursuant to Section 2.2(a) above, but the holders thereof shall be entitled only
to such rights as are granted by Section 262 of the DGCL. Each holder of
Dissenting Shares who becomes entitled to payment for such shares pursuant to
Section 262 of the DGCL shall receive payment therefor from the Surviving
Company in accordance with such laws; provided, however, that if any such holder
of Dissenting Shares shall have effectively withdrawn such holder's demand for
appraisal of such shares or lost such holder's right to appraisal and payment of
such shares under Section 262 of the DGCL, such holder or holders (as the case
may be) shall forfeit the right to appraisal of such shares and each such share
shall thereupon be deemed to have been canceled, extinguished and converted, as
of the Effective Time, into and represent the right to receive payment from
Atlantic of shares of Atlantic Common Stock as provided in Section 2.2(a) above.
(b) Any payments in respect of Dissenting Shares will be deemed made
by the Surviving Company.
2.6 Directors and Officers of the Surviving Corporation. From and after
the Effective Time, the directors and officers of the Surviving Company shall be
the persons who were directors of Manhattan immediately prior to the Effective
Time and the officers of Manhattan immediately prior to the Effective Time.
These directors and officers of the Surviving Company shall hold office for the
term specified in, and subject to the provisions contained in, the Certificate
of Incorporation and Bylaws of the Surviving Company and applicable law. If, at
or after the Effective Time, a vacancy shall exist on the board of directors or
in any of the offices of the Surviving Company, such vacancy shall be filled in
the manner provided in the Certificate of Incorporation and Bylaws of the
Surviving Company.
2.7 Directors and Officers of Atlantic. Immediately after the Effective
Time, the board of directors of Atlantic will consist of the following four (4)
persons: David M. Tanen, Joshua Kazam, Michael Weiser and Joan Pons. Immediately
after the Effective Time, the board of directors of Atlantic will elect the
officers of Manhattan immediately prior to the Effective Time as the officers of
Atlantic. The initial directors and officers of Atlantic shall hold office for
the term specified in, and subject to the provisions contained in, the
Certificate of Incorporation and Bylaws of Atlantic and applicable law.
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF MANHATTAN
Manhattan hereby represents and warrants as follows:
3.1 Organization and Qualification. Manhattan is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Delaware, and has the requisite corporate power to carry on its business as now
conducted. The copies of the Certificate of Incorporation and Bylaws of
Manhattan that have been made available to Atlantic prior to the date of this
Agreement are correct and complete copies of such documents as in effect as of
the date hereof. Manhattan is licensed or qualified to do business in every
jurisdiction in which the nature of its business or its ownership of property
requires it to be licensed or qualified, except
8
where the failure to be so licensed or qualified would not have a Material
Adverse Effect on Manhattan or the Surviving Company.
3.2 Authority Relative to this Agreement; Non-Contravention. Manhattan has
the requisite corporate power and authority to enter into this Agreement and to
carry out its obligations hereunder. The execution and delivery of this
Agreement by Manhattan and the consummation by Manhattan of the transactions
contemplated hereby have been duly authorized by the Board of Directors of
Manhattan and, except for approval of this Agreement and the Merger by the
requisite vote of Manhattan's stockholders (the "Requisite Manhattan Stockholder
Vote"), no other corporate proceedings on the part of Manhattan are necessary to
authorize the execution and delivery of this Agreement and the consummation of
the transactions contemplated hereby. This Agreement has been duly executed and
delivered by Manhattan and, assuming it is a valid and binding obligation of
Atlantic and MPAC, constitutes a valid and binding obligation of Manhattan
enforceable in accordance with its terms except as enforcement may be limited by
general principles of equity whether applied in a court of law or a court of
equity and by bankruptcy, insolvency and similar laws affecting creditors'
rights and remedies generally. Except as set forth in Schedule 3.2, Manhattan is
not subject to, or obligated under, any provision of (a) its Certificate of
Incorporation or Bylaws, (b) any agreement, arrangement or understanding, (c)
any license, franchise or permit or (d) subject to obtaining the approvals
referred to in the next sentence, any law, regulation, order, judgment or
decree, which would conflict with, be breached or violated, or in respect of
which a right of termination or acceleration or any security interest, charge or
encumbrance on any of its assets would be created, by the execution, delivery or
performance of this Agreement, or the consummation of the transactions
contemplated hereby, other than any such conflicts, breaches, violations, rights
of termination or acceleration or security interests, charges or encumbrances
which, in the aggregate, could not reasonably be expected to result in a
Material Adverse Effect on Manhattan or the Surviving Company. Except for (a)
approvals under applicable Blue Sky laws, (b) the filing of the Certificate of
Merger with the Secretary of State of Delaware, and (c) such filings,
authorizations or approvals as may be set forth in Schedule 3.2, no
authorization, consent or approval of, or filing with, any public body, court or
authority is necessary on the part of Manhattan for the consummation by
Manhattan of the transactions contemplated by this Agreement, except for such
authorizations, consents, approvals and filings as to which the failure to
obtain or make the same would not, in the aggregate, reasonably be expected to
have a Material Adverse Effect on Manhattan or the Surviving Company or
adversely affect the consummation of the transactions contemplated hereby.
3.3 Capitalization.
(a) The authorized, issued and outstanding shares of capital stock
of Manhattan as of the date hereof are correctly set forth on Schedule 3.3(a).
The issued and outstanding shares of capital stock of Manhattan are duly
authorized, validly issued, fully paid and nonassessable and have not been
issued in violation of any preemptive rights, and to Manhattan's Knowledge, are
free from any restrictions on transfer (other than restrictions under the
Securities Act or state securities laws) or any option, lien, pledge, security
interest, encumbrance or charge of any kind. Other than as described on Schedule
3.3, Manhattan has no other equity securities or securities containing any
equity features authorized, issued or
9
outstanding. Except as set forth in Schedule 3.3(a) hereto, there are no
agreements or other rights or arrangements existing which provide for the sale
or issuance of capital stock by Manhattan and there are no rights,
subscriptions, warrants, options, conversion rights or agreements of any kind
outstanding to purchase or otherwise acquire from Manhattan any shares of
capital stock or other securities of Manhattan of any kind. Except as set forth
on Schedule 3.3, there are no agreements or other obligations (contingent or
otherwise) which may require Manhattan to repurchase or otherwise acquire any
shares of its capital stock.
(b) Schedule 3.3(b) contains a list of the names and addresses of
the owners of record as of the date of this Agreement of all issued and
outstanding shares of Manhattan Common Stock and the number of shares of
Manhattan Common Stock each of them holds. Each of the Manhattan stockholders
noted in Schedule 3.3(b) as having done so has entered into a voting agreement
with Atlantic in the form attached as Exhibit B. Such Manhattan stockholders
collectively hold a majority of the outstanding shares of Manhattan Common
Stock.
(c) Manhattan does not own, and is not party to any contract to
acquire, any equity securities or other securities of any entity or any direct
or indirect equity or ownership interest in any other entity. To Manhattan's
Knowledge, there exist no voting trusts, proxies, or other contracts with
respect to the voting of shares of capital stock of Manhattan.
3.4 Litigation. There are no actions, suits, proceedings, orders or
investigations pending or, to the Knowledge of Manhattan, threatened against
Manhattan, at law or in equity, or before or by any federal, state or other
governmental department, commission, board, bureau, agency or instrumentality,
domestic or foreign.
3.5 No Brokers or Finders. Except as disclosed on Schedule 3.5, there are
no claims for brokerage commissions, finders' fees, investment advisory fees or
similar compensation in connection with the transactions contemplated by this
Agreement based on any arrangement, understanding, commitment or agreement made
by or on behalf of Manhattan.
3.6 Tax Matters.
(a) (i) Manhattan has timely filed (or has had timely filed on its
behalf) all returns, declarations, reports, estimates, information returns, and
statements, including any schedules and amendments to such documents ("Manhattan
Returns"), required to be filed or sent by it in respect of any Taxes or
required to be filed or sent by it by any taxing authority having jurisdiction;
(ii) all such Manhattan Returns are complete and accurate in all material
respects; (iii) Manhattan has timely and properly paid (or has had paid on its
behalf) all Taxes required to be paid by it; (iv) Manhattan has established on
the Manhattan Latest Balance Sheet, in accordance with GAAP, reserves that are
adequate for the payment of any Taxes not yet due and payable; (v) Manhattan has
complied with all applicable laws, rules, and regulations relating to the
collection or withholding of Taxes from third parties (including without
limitation employees) and the payment thereof (including, without limitation,
withholding of Taxes under Sections 1441 and 1442 of the Code, or similar
provisions under any foreign laws).
(b) There are no liens for Taxes upon any assets of Manhattan,
except liens for Taxes not yet due.
10
(c) No deficiency for any Taxes has been proposed, asserted or
assessed against Manhattan that has not been resolved and paid in full or is not
being contested in good faith. Except as disclosed in Schedule 3.6, no waiver,
extension or comparable consent given by Manhattan regarding the application of
the statute of limitations with respect to any Taxes or Returns is outstanding,
nor is any request for any such waiver or consent pending. Except as disclosed
in Schedule 3.6, there has been no Tax audit or other administrative proceeding
or court proceeding with regard to any Taxes or Manhattan Returns, nor is any
such Tax audit or other proceeding pending, nor has there been any notice to
Manhattan by any Taxing authority regarding any such Tax audit or other
proceeding, or, to the Knowledge of Manhattan, is any such Tax audit or other
proceeding threatened with regard to any Taxes or Manhattan Returns. Manhattan
does not expect the assessment of any additional Taxes of Manhattan for any
period prior to the date hereof and has no Knowledge of any unresolved
questions, claims or disputes concerning the liability for Taxes of Manhattan
which would exceed the estimated reserves established on its books and records.
(d) Except as set forth on Schedule 3.6, Manhattan is not a party to
any agreement, contract or arrangement that would result, separately or in the
aggregate, in the payment of any "excess parachute payments" within the meaning
of Section 280G of the Code and the consummation of the transactions
contemplated by this Agreement will not be a factor causing payments to be made
by Manhattan not to be deductible (in whole or in part) under Section 280G of
the Code. Manhattan is not liable for Taxes of any other person, and is not
currently under any contractual obligation to indemnify any person with respect
to Taxes, or a party to any tax sharing agreement or any other agreement
providing for payments by Manhattan with respect to Taxes. Manhattan is not a
party to any joint venture, partnership or other arrangement or contract which
could be treated as a partnership for federal income tax purposes. Manhattan has
not agreed and is not required, as a result of a change in method of accounting
or otherwise, to include any adjustment under Section 481 of the Code (or any
corresponding provision of state, local or foreign law) in taxable income.
Schedule 3.6 contains a list of all jurisdictions in which Manhattan is required
to file any Manhattan Return and no claim has ever been made by a taxing
authority in a jurisdiction where Manhattan does not currently file Manhattan
Returns that Manhattan is or may be subject to taxation by that jurisdiction.
There are no advance rulings in respect of any Tax pending or issued by any
Taxing authority with respect to any Taxes of Manhattan. Manhattan has not
entered into any gain recognition agreements under Section 367 of the Code and
the regulations promulgated thereunder. Manhattan is not liable with respect to
any indebtedness the interest of which is not deductible for applicable federal,
foreign, state or local income tax purposes. Manhattan has not filed or been
included in a combined, consolidated or unitary Tax return (or the substantial
equivalent thereof) of any person.
(e) Manhattan has been neither a "distributing corporation" nor a
"controlled corporation" (within the meaning of Section 355 of the Code) in a
distribution of stock qualifying for tax-free treatment under Section 355 of the
Code.
11
(f) Except as set forth on Schedule 3.6, Manhattan has not requested
any extension of time within which to file any Manhattan Return, which return
has not since been filed.
3.7 Contracts and Commitments. Contracts and Commitments.
(a) Schedule 3.7 hereto lists the following agreements, whether oral
or written, to which Manhattan is a party, which are currently in effect, and
which relate to the operation of Manhattan's business: (i) collective bargaining
agreement or contract with any labor union; (ii) bonus, pension, profit sharing,
retirement or other form of deferred compensation plan; (iii) hospitalization
insurance or other welfare benefit plan or practice, whether formal or informal;
(iv) stock purchase or stock option plan; (v) contract for the employment of any
officer, individual employee or other person on a full-time or consulting basis
or relating to severance pay for any such person; (vi) confidentiality
agreement; (vii) contract, agreement or understanding relating to the voting of
Manhattan Common Stock or the election of directors of Manhattan; (viii)
agreement or indenture relating to the borrowing of money or to mortgaging,
pledging or otherwise placing a lien on any of the assets of Manhattan; (ix)
guaranty of any obligation for borrowed money or otherwise; (x) lease or
agreement under which Manhattan is lessee of, or holds or operates any property,
real or personal, owned by any other party, for which the annual rental exceeds
$10,000; (xi) lease or agreement under which Manhattan is lessor of, or permits
any third party to hold or operate, any property, real or personal, for which
the annual rental exceeds $10,000; (xii) contract which prohibits Manhattan from
freely engaging in business anywhere in the world; (xiii) license agreement or
agreement providing for the payment or receipt of royalties or other
compensation by Manhattan in connection with the intellectual property rights
listed in Schedule 3.20(b) hereto; (xiv) contract or commitment for capital
expenditures in excess of $10,000; (xv) agreement for the sale of any capital
asset; or (xvi) other agreement which is either material to Manhattan's business
or was not entered into in the ordinary course of business.
(b) To Manhattan's Knowledge, Manhattan has performed all
obligations required to be performed by it in connection with the contracts or
commitments required to be disclosed in Schedule 3.7 hereto and is not in
receipt of any claim of default under any contract or commitment required to be
disclosed under such caption; Manhattan has no present expectation or intention
of not fully performing any material obligation pursuant to any contract or
commitment required to be disclosed under such caption; and Manhattan has no
Knowledge of any breach or anticipated breach by any other party to any contract
or commitment required to be disclosed under such caption.
3.8 Affiliate Transactions. Except as set forth in Schedule 3.8 hereto,
and other than pursuant to this Agreement, no officer, director or employee of
Manhattan, or any member of the immediate family of any such officer, director
or employee, or any entity in which any of such persons owns any beneficial
interest (other than any publicly-held corporation whose stock is traded on a
national securities exchange or in the over-the-counter market and less than
five percent of the stock of which is beneficially owned by any of such persons)
(collectively "Manhattan Insiders"), has any agreement with Manhattan (other
than normal employment arrangements) or any interest in any property, real,
personal or mixed, tangible or intangible, used in or pertaining to the business
of Manhattan (other than ownership of capital stock of
12
Manhattan). Except as set forth on Schedule 3.8, Manhattan is not indebted to
any Manhattan Insider (except for amounts due as normal salaries and bonuses and
in reimbursement of ordinary business expenses) and no Manhattan Insider is
indebted to Manhattan (except for cash advances for ordinary business expenses).
None of the Manhattan Insiders has any direct or indirect interest in any
competitor, supplier or customer of Manhattan or in any person, firm or entity
from whom or to whom Manhattan leases any property, or in any other person, firm
or entity with whom Manhattan transacts business of any nature. For purposes of
this Section 3.8, the members of the immediate family of an officer, director or
employee shall consist of the spouse, parents, children and siblings of such
officer, director or employee.
3.9 Compliance with Laws; Permits.
(a) Except for any noncompliance that would not reasonably be
expected to have a Material Adverse Effect on Manhattan or the Surviving
Company, Manhattan and its officers, directors, agents and employees have
complied with all applicable laws, regulations and other requirements,
including, but not limited to, federal, state, local and foreign laws,
ordinances, rules, regulations and other requirements pertaining to equal
employment opportunity, employee retirement, affirmative action and other hiring
practices, occupational safety and health, workers' compensation, unemployment
and building and zoning codes, and no claims have been filed against Manhattan,
and Manhattan has not received any notice, alleging a violation of any such
laws, regulations or other requirements. Manhattan is not relying on any
exemption from or deferral of any such applicable law, regulation or other
requirement that would not be available to Atlantic after it acquires
Manhattan's properties, assets and business.
(b) Manhattan has, in full force and effect, all licenses, permits
and certificates, from federal, state, local and foreign authorities (including,
without limitation, federal and state agencies regulating occupational health
and safety) necessary to conduct its business and operate its properties
(collectively, the "Manhattan Permits"). A true, correct and complete list of
all the Manhattan Permits is set forth in Schedule 3.9 hereto. To the Knowledge
of Manhattan, Manhattan has conducted its business in compliance with all
material terms and conditions of the Manhattan Permits, except for any
noncompliance that would not reasonably be expected to have a Material Adverse
Effect on Manhattan or the Surviving Company.
3.10 Financial Statements. Manhattan has made available to Atlantic
audited balance sheets of Manhattan as of December 31, 2001 and as of September
30, 2002, and the related audited statements of income, changes in stockholders'
equity, and cash flows of Manhattan for the periods then ended (the "Manhattan
Financial Statements"). The Manhattan Financial Statements have been prepared in
accordance with GAAP consistently applied with past practice (except in each
case as described in the notes thereto) and on that basis present fairly, in all
material respects, the financial position and the results of operations, changes
in stockholders' equity, and cash flows of Manhattan as of the date of and for
the period referred to in the Manhattan Financial Statements.
3.11 Books and Records. The books of account, minute books, stock record
books, and other records of Manhattan, complete copies of which have been made
available to Atlantic, have been properly kept and contain no inaccuracies
except for inaccuracies that would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect on
13
Manhattan or the Surviving Company. At the Closing, all of Manhattan's records
will be in the possession of Manhattan.
3.12 Real Property. Manhattan does not own any real property. Schedule
3.12 contains an accurate list of all leaseholds and other interests of
Manhattan in any real property. Manhattan has good and valid title to those
leaseholds and other interests free and clear of all liens and encumbrances, and
the real property to which those leasehold and other interests pertain
constitutes the only real property used in Manhattan's business.
3.13 Insurance. The insurance policies owned and maintained by Manhattan
that are material to Manhattan are in full force and effect, all premiums due
and payable thereon have been paid (other than retroactive or retrospective
premium adjustments that Manhattan is not currently required, but may in the
future be required, to pay with respect to any period ending prior to the date
of this Agreement), and Manhattan has received no notice of cancellation or
termination with respect to any such policy that has not been replaced on
substantially similar terms prior to the date of such cancellation.
3.14 No Undisclosed Liabilities. Except as reflected in the audited
balance sheet of Manhattan at September 30, 2002 (the "Manhattan Latest Balance
Sheet"), Manhattan has no liabilities (whether accrued, absolute, contingent,
unliquidated or otherwise except (i) liabilities which have arisen after the
date of the Manhattan Latest Balance Sheet in the ordinary course of business
(none of which is a material uninsured liability for breach of contract, breach
of warranty, tort, infringement, claim or lawsuit), or (ii) as otherwise set
forth in Schedule 3.14.
3.15 Environmental Matters. None of the operations of Manhattan involves
the generation, transportation, treatment, storage or disposal of hazardous
waste, as defined under 40 C.F.R. Parts 260-270 or any state, local or foreign
equivalent.
3.16 Absence of Certain Developments. Except as set forth in Schedule 3.16
or as disclosed in the Manhattan Financial Statements or as otherwise
contemplated by this Agreement, since September 30, 2002, Manhattan has
conducted its business only in the ordinary course consistent with past practice
and there has not occurred (i) any event having a Material Adverse Effect on
Manhattan or the Surviving Company, (ii) any event that would reasonably be
expected to prevent or materially delay the performance of Manhattan's
obligations pursuant to this Agreement, (iii) any material change by Manhattan
in its accounting methods, principles or practices, (iv) any declaration,
setting aside or payment of any dividend or distribution in respect of the
shares of capital stock of Manhattan or any redemption, purchase or other
acquisition of any of Manhattan's securities, (v) any increase in the
compensation or benefits or establishment of any bonus, insurance, severance,
deferred compensation, pension, retirement, profit sharing, stock option
(including, without limitation, the granting of stock options, stock
appreciation rights, performance awards or restricted stock awards), stock
purchase or other employee benefit plan of Manhattan, or any other increase in
the compensation payable or to become payable to any employees, officers,
consultants or directors of Manhattan, (vi) other than issuances of options
pursuant to duly adopted option plans, any issuance, grants or sale of any
stock, options, warrants, notes, bonds or other securities, or entry into any
agreement with respect thereto by Manhattan, (vii) any amendment to the
Certificate of Incorporation or Bylaws of Manhattan, (viii) other than in the
ordinary course of business consistent with past practice, any (w) capital
14
expenditures by Manhattan, (x) purchase, sale, assignment or transfer of any
material assets by Manhattan, (y) mortgage, pledge or existence of any lien,
encumbrance or charge on any material assets or properties, tangible or
intangible of Manhattan, except for liens for taxes not yet due and such other
liens, encumbrances or charges which do not, individually or in the aggregate,
have a Material Adverse Effect on Manhattan or the Surviving Company, or (z)
cancellation, compromise, release or waiver by Manhattan of any rights of
material value or any material debts or claims, (ix) any incurrence by Manhattan
of any material liability (absolute or contingent), except for current
liabilities and obligations incurred in the ordinary course of business
consistent with past practice, (x) damage, destruction or similar loss, whether
or not covered by insurance, materially affecting the business or properties of
Manhattan, (xi) entry into any agreement, contract, lease or license other than
in the ordinary course of business consistent with past practice, (xii) any
acceleration, termination, modification or cancellation of any agreement,
contract, lease or license to which Manhattan is a party or by which it is
bound, (xiii) entry by Manhattan into any loan or other transaction with any
officers, directors or employees of Manhattan, (xiv) any charitable or other
capital contribution by Manhattan or pledge therefore, (xv) entry by Manhattan
into any transaction of a material nature other than in the ordinary course of
business consistent with past practice, or (xvi) any negotiation or agreement by
the Manhattan to do any of the things described in the preceding clauses (i)
through (xv).
3.17 Employee Benefit Plans. (a) Schedule 3.17(a) lists all material (i)
"employee benefit plans," within the meaning of Section 3(3) of ERISA, of
Manhattan, (ii) bonus, stock option, stock purchase, stock appreciation right,
incentive, deferred compensation, supplemental retirement, severance, and fringe
benefit plans, programs, policies or arrangements, and (iii) employment or
consulting agreements, for the benefit of, or relating to, any current or former
employee (or any beneficiary thereof) of Manhattan, in the case of a plan
described in (i) or (ii) above, that is currently maintained by Manhattan or
with respect to which Manhattan has an obligation to contribute, and in the case
of an agreement described in (iii) above, that is currently in effect (the
"Manhattan Plans"). Manhattan has heretofore made available to Atlantic true and
complete copies of the Manhattan Plans and any amendments thereto, any related
trust, insurance contract, summary plan description, and, to the extent required
under ERISA or the Code, the most recent annual report on Form 5500 and
summaries of material modifications.
(b) No Manhattan Plan is (1) a "multiemployer plan" within the
meaning of Sections 3(37) or 4001(a)(3) of ERISA, (2) a "multiple employer plan"
within the meaning of Section 3(40) of ERISA or Section 413(c) of the Code, or
(3) is subject to Title IV of ERISA or Section 412 of the Code.
(c) Except as set forth in Schedule 3.17(c), there is no proceeding
pending or, to Manhattan's Knowledge, threatened against the assets of any
Manhattan Plan or, with respect to any Manhattan Plan, against Manhattan other
than proceedings that would not reasonably be expected to result in a material
liability, and to Manhattan's Knowledge there is no proceeding pending or
threatened in writing against any fiduciary of any Manhattan Plan other than
proceedings that would not reasonably be expected to result in a material
liability.
(d) Each of the Manhattan Plans has been operated and administered
in all material respects in accordance with its terms and applicable law,
including, but not limited to, ERISA and the Code.
15
(e) Each of the Manhattan Plans that is intended to be "qualified"
within the meaning of Section 401(a) of the Code has received a favorable
determination, notification, or opinion letter from the IRS.
(f) Except as set forth in Schedule 3.17(f), no director, officer,
or employee of Manhattan will become entitled to retirement, severance or
similar benefits or to enhanced or accelerated benefits (including any
acceleration of vesting or lapsing of restrictions with respect to equity-based
awards) under any Manhattan Plan solely as a result of consummation of the
transactions contemplated by this Agreement.
3.18 Employees.
(a) Schedule 3.18 lists the following information for each employee
and each director of Manhattan as of the date of this Agreement, including each
employee on leave of absence or layoff status: (1) name; (2) job title; (3)
current annual base salary or annualized wages; (4) bonus compensation earned
during 2001; (5) vacation accrued and unused; (6) service credited for purposes
of vesting and eligibility to participate under Manhattan Plans; and (7) the
number of shares of Manhattan Common Stock beneficially owned by each such
employee. Schedule 3.18 also lists the following information for each consultant
or advisory board member of Manhattan, as of the date of this Agreement: (x)
name; (y) services performed in 2001 and 2002; and (z) compensation received
from Manhattan with respect to services performed in 2001 and 2002.
(b) Except as otherwise set forth in Schedule 3.18, or as
contemplated by this Agreement, to the Knowledge of Manhattan, (i) neither any
executive employee of Manhattan nor any group of Manhattan's employees has any
plans to terminate his, her or its employment; (ii) Manhattan has no material
labor relations problem pending and its labor relations are satisfactory; (iii)
there are no workers' compensation claims pending against Manhattan nor is
Manhattan aware of any facts that would give rise to such a claim; (iv) to the
Knowledge of Manhattan, no employee of Manhattan is subject to any secrecy or
noncompetition agreement or any other agreement or restriction of any kind that
would impede in any way the ability of such employee to carry out fully all
activities of such employee in furtherance of the business of Manhattan; and (v)
no employee or former employee of Manhattan has any claim with respect to any
intellectual property rights of Manhattan set forth in Schedule 3.20(b) hereto.
3.19 Proprietary Information and Inventions. Each current Manhattan
employee, consultant, and advisory board member is party to either a
non-disclosure agreement in the form attached as Schedule 3.19 or other
agreement relating to employment with Manhattan and containing comparable
non-disclosure provisions. To Manhattan's Knowledge, no current or former
Manhattan employee, consultant or advisory board member who is party to a
non-disclosure agreement has breached that non-disclosure agreement. To
Manhattan's Knowledge, no current Manhattan employee, consultant or advisory
board member who is party to an alternative employment agreement with Manhattan
has breached the non-disclosure provisions of that agreement.
16
3.20 Intellectual Property. (a) Except as set forth in Schedule 3.20(a),
Manhattan owns or has valid and enforceable licenses to use all of the following
used in or necessary to conduct its business as currently conducted
(collectively, the "Manhattan Intellectual Property"):
(1) patents (including any registrations, continuations,
continuations in part, renewals, and any applications for any of the
foregoing) (collectively, "Patents");
(2) registered and unregistered copyrights and copyright
applications (collectively, "Copyrights");
(3) registered and unregistered trademarks, service marks, trade
names, slogans, logos, designs and general intangibles of the like nature,
together with all registrations and applications therefor (collectively,
"Trademarks");
(4) trade secrets, confidential or proprietary technical
information, know-how, designs, processes, research in progress,
inventions and invention disclosures (whether patentable or unpatentable)
(collectively, "Know-How");
(5) software (together with Patents, Copyrights, Trademarks, and
Know-How, "Intellectual Property").
(b) Set forth on Schedule 3.20(b) is a complete and accurate list of
all Patents, Trademarks, registered or material Copyrights and software owned or
licensed by Manhattan. Schedule 3.20(b) sets forth a complete and accurate list
of all Persons from which or to which Manhattan licenses any material
Intellectual Property.
(c) Manhattan is the sole and exclusive owner of the Manhattan
Intellectual Property its purports to own, free and clear of all liens and
encumbrances and free of all licenses except those set forth in Schedule 3.20(c)
and licenses relating to off-the-shelf software having a per-application
acquisition price of less than $5,000. No Copyright registration, Trademark
registration, or Patent set forth in Schedule 3.20(b) has lapsed, expired or
been abandoned or cancelled, or is subject to any pending or, to Manhattan's
Knowledge, threatened opposition or cancellation proceeding in any country.
(d) Except as set forth in Schedule 3.20(d), to Manhattan's
Knowledge (1) neither the conduct of Manhattan's business nor the manufacture,
marketing, licensing, sale, distribution or use of its products or services
infringes upon the proprietary rights of any Person, and (2) there are no
infringements of the Manhattan Intellectual Property by any Person. Except as
set forth in Schedule 3.20(a) and Schedule 3.20(c), there are no claims pending
or, to Manhattan's Knowledge, threatened (1) alleging that Manhattan's business
as currently conducted infringes upon or constitutes an unauthorized use or
violation of the proprietary rights of any Person, or (2) alleging that the
Manhattan Intellectual Property is being infringed by any Person, or (3)
challenging the ownership, validity or enforceability of the Manhattan
Intellectual Property.
(e) Manhattan has not entered into any consent agreement,
indemnification agreement, forbearance to sue, settlement agreement or
cross-licensing arrangement with any
17
Person relating to the Manhattan Intellectual Property other than as part of the
license agreements listed in Schedule 3.20(b) or set forth in Schedule 3.20(c).
(f) Except as set forth in Schedule 3.20(f), Manhattan is not, nor
will it be as a result of the execution and delivery of this Agreement or the
performance of its obligations under this Agreement, in breach of any license,
sublicense or other contract relating to the Manhattan Intellectual Property
that would reasonably be expected, individually or in the aggregate, to have a
Material Adverse Effect on Manhattan or the Surviving Company.
3.21 Tax-Free Reorganization. Neither Manhattan nor, to Manhattan's
Knowledge, any of its Affiliates has through the date of this Agreement taken or
agreed to take any action that would prevent the Merger from qualifying as a
reorganization under Section 368(a) of the Code.
3.22 Vote Required. The affirmative vote of a majority of the votes that
holders of the outstanding shares of Manhattan Common Stock are entitled to cast
is the only vote of the holders of any class or series of Manhattan capital
stock necessary to approve the Merger.
3.23 Full Disclosure. The representations and warranties of Manhattan
contained in this Agreement (and in any schedule, exhibit, certificate or other
instrument to be delivered under this Agreement) are true and correct in all
material respects, and such representations and warranties do not omit any
material fact necessary to make the statements contained therein, in light of
the circumstances under which they were made, not misleading. There is no fact
of which Manhattan has Knowledge that has not been disclosed to Atlantic
pursuant to this Agreement, including the schedules hereto, all taken together
as a whole, which has had or could reasonably be expected to have a Material
Adverse Effect on Manhattan or the Surviving Company or materially adversely
affect the ability of Manhattan to consummate in a timely manner the
transactions contemplated hereby.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF ATLANTIC AND MPAC
Atlantic and MPAC hereby represent and warrant to Manhattan as follows:
4.1 Organization and Qualification. Atlantic and MPAC are each
corporations duly organized, validly existing and in good standing under the
laws of the State of Delaware, and each has the requisite corporate power to
carry on their respective businesses as now conducted. Each of the Atlantic
Subsidiaries is a corporation duly organized, validly existing and in good
standing under the laws of the state of its incorporation. The copies of the
Certificate of Incorporation and Bylaws of Atlantic and MPAC which have been
made available to Manhattan on or prior to the date of this Agreement are
correct and complete copies of such documents as in effect as of the date of
this Agreement. Each of Atlantic and the Atlantic Subsidiaries is licensed or
qualified to do business in every jurisdiction which the nature of its business
or its ownership of property requires it to be licensed or qualified, except
where the failure to be so licensed or qualified would not have a Material
Adverse Effect on Atlantic or any Atlantic Subsidiary.
18
4.2 Authority Relative to this Agreement; Non-Contravention. Each of
Atlantic and MPAC has the requisite corporate power and authority to enter into
this Agreement, and to carry out its obligations hereunder. The execution and
delivery of this Agreement by Atlantic and MPAC, and the consummation by
Atlantic and MPAC of the transactions contemplated hereby have been duly
authorized by the Boards of Directors of Atlantic and MPAC. Except for approval
by the Atlantic stockholders of the Atlantic Proposals in accordance with the
DGCL and the Atlantic Certificate of Incorporation and Bylaws (collectively, the
"Requisite Atlantic Stockholder Votes"), no other corporate proceedings on the
part of Atlantic or MPAC are necessary to authorize the execution and delivery
of this Agreement and the consummation of the transactions contemplated hereby
or will otherwise be sought by Atlantic. This Agreement has been duly executed
and delivered by Atlantic and MPAC and, assuming it is a valid and binding
obligation of Manhattan, constitutes a valid and binding obligation of Atlantic
and MPAC enforceable in accordance with its terms except as enforcement may be
limited by general principles of equity whether applied in a court of law or a
court of equity and by bankruptcy, insolvency and similar laws affecting
creditors' rights and remedies generally. Except as set forth in Schedule 4.2,
neither Atlantic nor any of the Atlantic Subsidiaries is subject to, nor
obligated under, any provision of (a) its Articles or Bylaws, (b) any agreement,
arrangement or understanding, (c) any license, franchise or permit, nor (d)
subject to obtaining the approvals referred to in the next sentence, any law,
regulation, order, judgment or decree, which would conflict with, be breached or
violated, or in respect of which a right of termination or acceleration or any
security interest, charge or encumbrance on any of its assets would be created,
by the execution, delivery or performance of this Agreement or the consummation
of the transactions contemplated hereby, other than any such conflicts,
breaches, violations, rights of termination or acceleration or security
interests, charges or encumbrances which, in the aggregate, could not reasonably
be expected to have a Material Adverse Effect on Atlantic or any Atlantic
Subsidiaries. Except for (a) approvals under applicable Blue Sky laws, (b) the
filing of the Certificate of Merger with the Delaware Secretary of State, and
(c) such filings, authorizations or approvals as may be set forth in Schedule
4.2, no authorization, consent or approval of, or filing with, any public body,
court or authority is necessary on the part of Atlantic or any Atlantic
Subsidiary for the consummation by Atlantic or MPAC of the transactions
contemplated by this Agreement, except for such authorizations, consents,
approvals and filings as to which the failure to obtain or make the same would
not, in the aggregate, reasonably be expected to have a Material Adverse Effect
on Atlantic or MPAC.
4.3 Capitalization.
(a) The authorized, issued and outstanding shares of capital stock
of Atlantic as of the date hereof are correctly set forth on Schedule 4.3(a).
The issued and outstanding shares of capital stock of Atlantic are duly
authorized, validly issued, fully paid and nonassessable and have not been
issued in violation of any preemptive rights. Other than as described on
Schedule 4.3, Atlantic has no other equity securities or securities containing
any equity features authorized, issued or outstanding. Except as set forth in
Schedule 4.3(a) hereto, there are no agreements or other rights or arrangements
existing which provide for the sale or issuance of capital stock by Atlantic and
there are no rights, subscriptions, warrants, options, conversion rights or
agreements of any kind outstanding to purchase or otherwise acquire from
Atlantic any shares of capital stock or other securities of Atlantic of any
kind. Except as set forth
19
on Schedule 4.3, there are no agreements or other obligations (contingent or
otherwise) which may require Atlantic to repurchase or otherwise acquire any
shares of its capital stock.
(b) To Atlantic's Knowledge, there exist no voting trusts, proxies,
or other contracts with respect to the voting of shares of capital stock of
Atlantic.
(c) The authorized capital of MPAC consists of 1,000 shares of
common stock, par value $.01 per share, all of which are issued and outstanding
and held of record by Atlantic as of the date hereof. The issued and outstanding
shares of capital stock of MPAC are duly authorized, validly issued, fully paid
and nonassessable and have not been issued in violation of any preemptive
rights. Except as disclosed on Schedule 4.3(c), there are no options, warrants,
conversion privileges or other rights, agreements, arrangements or commitments
obligating MPAC to issue, sell, purchase or redeem any shares of its capital
stock or securities or obligations of any kind convertible into or exchangeable
for any shares of its capital stock
4.4 Exchange Act Reports. Prior to the date of this Agreement, Atlantic
has delivered or made available to Manhattan complete and accurate copies of (a)
Atlantic's Annual Reports on Form 10-KSB (as amended) for the years ended
December 31, 1999, 2000 and 2001 (the "Atlantic 10-K Reports") as filed with the
SEC, (b) all Atlantic proxy statements and annual reports to stockholders used
in connection with meetings of Atlantic stockholders held since January 1, 2000,
other than the Proxy Statement (the "Atlantic Proxy Statements"); (c) Atlantic's
Quarterly Reports on Form 10-QSB for the quarters ended March 31, 2002, June 30,
2002 and September 30, 2002, respectively (the "Atlantic 10-Q Reports"), as
filed with the SEC; and (d) all current reports on Form 8-K filed with the SEC
after December 31, 2001 (the "Atlantic 8-K Reports," and together with the
Atlantic 10-K Reports, Atlantic Proxy Statements and Atlantic 10-Q Reports, the
"Atlantic SEC Filings"). As of their respective dates or as subsequently amended
prior to the date hereof, each of the Atlantic SEC Filings (i) did not contain
any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading and (ii)
complied as to form in all material respects with the applicable rules and
regulations of the SEC. Since January 1, 2001, Atlantic has filed in a timely
manner all reports that it was required to file with the SEC pursuant to Section
13(a), 14(a), 14(c) and 15(d) of the Exchange Act. The financial statements
(including footnotes thereto) included in or incorporated by reference into the
Atlantic 10-K Reports and the Atlantic 10-Q Reports were prepared in accordance
with GAAP applied on a consistent basis during the periods involved (except as
otherwise noted therein) and fairly present, in all material respects, the
financial condition of Atlantic as of the dates thereof and results of
operations for the periods referred to therein.
4.5 Subsidiaries. Schedule 4.5 correctly sets forth the name and
jurisdiction of incorporation of each subsidiary of Atlantic (each a "Atlantic
Subsidiary" and collectively, the "Atlantic Subsidiaries"). Except as disclosed
on Schedule 4.5, all of the issued and outstanding shares of capital stock of
each Atlantic Subsidiary are owned directly by Atlantic free and clear of any
option, lien, pledge, security interest, encumbrance or charge of any kind. All
of the outstanding shares of capital stock of each Atlantic Subsidiary have been
duly and validly authorized and issued and are fully paid and nonassessable.
Except as set forth in Schedule 4.5,
20
Atlantic does not own any stock, partnership interest, joint venture interest or
any other security or ownership interest issued by any other corporation,
organization or entity.
4.6 Absence of Certain Developments. Except as set forth in Schedule 4.6
or as disclosed in the Atlantic SEC Filings or as otherwise contemplated by this
Agreement, since September 30, 2002, Atlantic and each Atlantic Subsidiary have
conducted their business only in the ordinary course consistent with past
practice and there has not occurred (i) any event having a Material Adverse
Effect on Atlantic or any Atlantic Subsidiary, (ii) any event that would
reasonably be expected to prevent or materially delay the performance of
Atlantic's obligations pursuant to this Agreement, (iii) any material change by
Atlantic or any Atlantic Subsidiary in its accounting methods, principles or
practices, (iv) any declaration, setting aside or payment of any dividend or
distribution in respect of the shares of capital stock of Atlantic or any
Atlantic Subsidiary or any redemption, purchase or other acquisition of any of
Atlantic's or any of Atlantic Subsidiary's securities, (v) any increase in the
compensation or benefits or establishment of any bonus, insurance, severance,
deferred compensation, pension, retirement, profit sharing, stock option
(including, without limitation, the granting of stock options, stock
appreciation rights, performance awards or restricted stock awards), stock
purchase or other employee benefit plan of Atlantic or any Atlantic Subsidiary,
or any other increase in the compensation payable or to become payable to any
employees, officers, consultants or directors of Atlantic or any Atlantic
subsidiary, (vi) other than issuances of options pursuant to duly adopted option
plans, any issuance, grants or sale of any stock, options, warrants, notes,
bonds or other securities, or entry into any agreement with respect thereto by
Atlantic and any Atlantic Subsidiary, (vii) any amendment to the Certificate of
Incorporation or Bylaws of Atlantic or any Atlantic Subsidiary, (viii) other
than in the ordinary course of business consistent with past practice, any (w)
capital expenditures by Atlantic or any Atlantic Subsidiary, (x) purchase, sale,
assignment or transfer of any material assets by Atlantic or any Atlantic
Subsidiary, (y) mortgage, pledge or existence of any lien, encumbrance or charge
on any material assets or properties, tangible or intangible of Atlantic or any
Atlantic Subsidiary, except for liens for taxes not yet due and such other
liens, encumbrances or charges which do not, individually or in the aggregate,
have a Material Adverse Effect on Atlantic, or (z) cancellation, compromise,
release or waiver by Atlantic or any Atlantic Subsidiary of any rights of
material value or any material debts or claims, (ix) any incurrence by Atlantic
or any Atlantic Subsidiary of any material liability (absolute or contingent),
except for current liabilities and obligations incurred in the ordinary course
of business consistent with past practice, (x) damage, destruction or similar
loss, whether or not covered by insurance, materially affecting the business or
properties of Atlantic, (xi) entry by Atlantic or any Atlantic Subsidiary into
any agreement, contract, lease or license other than in the ordinary course of
business consistent with past practice, (xii) any acceleration, termination,
modification or cancellation of any agreement, contract, lease or license to
which Atlantic or any Atlantic Subsidiary is a party or by which any of them is
bound, (xiii) entry by Atlantic or any Atlantic Subsidiary into any loan or
other transaction with any officers, directors or employees of Atlantic or any
Atlantic Subsidiary, (xiv) any charitable or other capital contribution by
Atlantic or any Atlantic Subsidiary or pledge therefore, (xv) entry by Atlantic
or any Atlantic Subsidiary into any transaction of a material nature other than
in the ordinary course of business consistent with past practice, or (xvi) any
negotiation or agreement by the Atlantic or any Atlantic Subsidiary to do any of
the things described in the preceding clauses (i) through (xv).
21
4.7 Absence of Undisclosed Liabilities. Except as reflected in the
unaudited consolidated balance sheet of Atlantic at September 30, 2002 included
in Atlantic's Quarterly Report on Form 10-QSB for such period (the "Atlantic
Latest Balance Sheet"), Atlantic has no liabilities (whether accrued, absolute,
contingent, unliquidated or otherwise except (i) liabilities which have arisen
after the date of the Atlantic Latest Balance Sheet in the ordinary course of
business (none of which is a material uninsured liability for breach of
contract, breach of warranty, tort, infringement, claim or lawsuit), or (ii) as
otherwise set forth in Schedule 4.7 attached hereto.
4.8 Litigation. Except as set forth in Schedule 4.8, as of the date
hereof, there are no actions, suits, proceedings, orders or investigations
pending or, to the Knowledge of Atlantic, threatened against Atlantic, at law or
in equity, or before or by any federal, state or other governmental department,
commission, board, bureau, agency or instrumentality, domestic or foreign.
4.9 No Brokers or Finders. Except as disclosed on Schedule 4.9, there are
no claims for brokerage commissions, finders' fees, investment advisory fees or
similar compensation in connection with the transactions contemplated by this
Agreement based on any arrangement, understanding, commitment or agreement made
by or on behalf of Atlantic.
4.10 Validity of the Atlantic Common Stock. The shares of Atlantic Common
Stock to be issued to holders of Manhattan Common Stock pursuant to this
Agreement will be, when issued, duly authorized, validly issued, fully paid and
nonassessable.
4.11 Tax Matters.
(a) (i) Atlantic and each Atlantic Subsidiary has timely filed (or
has had timely filed on its behalf) all returns, declarations, reports,
estimates, information returns, and statements, including any schedules and
amendments to such documents ("Atlantic Returns"), required to be filed or sent
by it in respect of any Taxes or required to be filed or sent by it by any
taxing authority having jurisdiction; (ii) all such Atlantic Returns are
complete and accurate in all material respects; (iii) Atlantic and each Atlantic
Subsidiary has timely and properly paid (or has had paid on its behalf) all
Taxes required to be paid by it; (iv) Atlantic has established on the Atlantic
Latest Balance Sheet, in accordance with GAAP, reserves that are adequate for
the payment of any Taxes not yet due and payable; (v) Atlantic and each Atlantic
Subsidiary has complied with all applicable laws, rules, and regulations
relating to the collection or withholding of Taxes from third parties (including
without limitation employees) and the payment thereof (including, without
limitation, withholding of Taxes under Sections 1441 and 1442 of the Code, or
similar provisions under any foreign laws).
(b) There are no liens for Taxes upon any assets of Atlantic or any
Atlantic Subsidiary, except liens for Taxes not yet due.
(c) No deficiency for any Taxes has been proposed, asserted or
assessed against Atlantic or any Atlantic Subsidiary that has not been resolved
and paid in full or is not being contested in good faith. Except as disclosed in
Schedule 4.11, no waiver, extension or comparable consent given by Atlantic or
any Atlantic Subsidiary regarding the application of the
22
statute of limitations with respect to any Taxes or Returns is outstanding, nor
is any request for any such waiver or consent pending. Except as disclosed in
Schedule 4.11, there has been no Tax audit or other administrative proceeding or
court proceeding with regard to any Taxes or Atlantic Returns, nor is any such
Tax audit or other proceeding pending, nor has there been any notice to Atlantic
or any Atlantic Subsidiary by any Taxing authority regarding any such Tax audit
or other proceeding, or, to the Knowledge of Atlantic, is any such Tax audit or
other proceeding threatened with regard to any Taxes or Atlantic Returns.
Atlantic does not expect the assessment of any additional Taxes of Atlantic or
any Atlantic Subsidiary for any period prior to the date hereof and has no
Knowledge of any unresolved questions, claims or disputes concerning the
liability for Taxes of Atlantic or any Atlantic Subsidiary which would exceed
the estimated reserves established on its books and records.
(d) Except as set forth on Schedule 4.11, neither Atlantic nor any
Atlantic Subsidiary is a party to any agreement, contract or arrangement that
would result, separately or in the aggregate, in the payment of any "excess
parachute payments" within the meaning of Section 280G of the Code and the
consummation of the transactions contemplated by this Agreement will not be a
factor causing payments to be made by Atlantic or any Atlantic Subsidiary not to
be deductible (in whole or in part) under Section 280G of the Code. Neither
Atlantic nor any Atlantic Subsidiary is liable for Taxes of any other person nor
is currently under any contractual obligation to indemnify any person with
respect to Taxes, or a party to any tax sharing agreement or any other agreement
providing for payments by Atlantic or any Atlantic Subsidiary with respect to
Taxes. Neither Atlantic nor any Atlantic Subsidiary is a party to any joint
venture, partnership or other arrangement or contract which could be treated as
a partnership for federal income tax purposes. Neither Atlantic nor any Atlantic
Subsidiary has agreed and is required, as a result of a change in method of
accounting or otherwise, to include any adjustment under Section 481 of the Code
(or any corresponding provision of state, local or foreign law) in taxable
income. Schedule 4.11 contains a list of all jurisdictions in which Atlantic or
any Atlantic Subsidiary is required to file any Atlantic Return and no claim has
ever been made by a taxing authority in a jurisdiction where Atlantic or any
Atlantic Subsidiary does not currently file Atlantic Returns that Atlantic or
any Atlantic Subsidiary is or may be subject to taxation by that jurisdiction.
There are no advance rulings in respect of any Tax pending or issued by any
Taxing authority with respect to any Taxes of Atlantic or any Atlantic
Subsidiary. Neither Atlantic nor any Atlantic Subsidiary has entered into any
gain recognition agreements under Section 367 of the Code and the regulations
promulgated thereunder. Neither Atlantic nor any Atlantic Subsidiary is liable
with respect to any indebtedness the interest of which is not deductible for
applicable federal, foreign, state or local income tax purposes.
(c) Atlantic has been neither a "distributing corporation" nor a
"controlled corporation" (within the meaning of Section 355 of the Code) in a
distribution of stock qualifying for tax-free treatment under Section 355 of the
Code.
(d) Except as set forth on Schedule 4.11, neither Atlantic nor any
Atlantic Subsidiary has requested any extension of time within which to file any
Atlantic Return, which return has not since been filed.
23
4.12 Contracts and Commitments.
(a) Schedule 4.12 hereto lists the following agreements, whether
oral or written, to which Atlantic or any Atlantic Subsidiary is a party, which
are currently in effect, and which relate to the operation of Atlantic's
business, or where applicable, the business of any Atlantic Subsidiary: (i)
collective bargaining agreement or contract with any labor union; (ii) bonus,
pension, profit sharing, retirement or other form of deferred compensation plan;
(iii) hospitalization insurance or other welfare benefit plan or practice,
whether formal or informal; (iv) stock purchase or stock option plan; (v)
contract for the employment of any officer, individual employee or other person
on a full-time or consulting basis or relating to severance pay for any such
person; (vi) confidentiality agreement; (vii) contract, agreement or
understanding relating to the voting of Atlantic Common Stock or the election of
directors of Atlantic; (viii) agreement or indenture relating to the borrowing
of money or to mortgaging, pledging or otherwise placing a lien on any of the
assets of Atlantic or any Atlantic Subsidiary; (ix) guaranty of any obligation
for borrowed money or otherwise; (x) lease or agreement under which Atlantic or
any Atlantic Subsidiary is lessee of, or holds or operates any property, real or
personal, owned by any other party, for which the annual rental exceeds $10,000;
(xi) lease or agreement under which Atlantic or any Atlantic Subsidiary is
lessor of, or permits any third party to hold or operate, any property, real or
personal, for which the annual rental exceeds $10,000; (xii) contract which
prohibits Atlantic or any Atlantic Subsidiary from freely engaging in business
anywhere in the world; (xiii) license agreement or agreement providing for the
payment or receipt of royalties or other compensation by Atlantic or any
Atlantic Subsidiary in connection with the intellectual property rights listed
in Schedule 4.13(b) hereto; (xiv) contract or commitment for capital
expenditures in excess of $10,000; (xv) agreement for the sale of any capital
asset; (xvi) contract with any Atlantic Subsidiary any affiliate thereof which
in any way relates to Atlantic (other than for employment on customary terms);
or (xvii) other agreement which is either material to Atlantic's business or was
not entered into in the ordinary course of business.
(b) To Atlantic's Knowledge, Atlantic and each Atlantic Subsidiary
has performed all obligations required to be performed by them in connection
with the contracts or commitments required to be disclosed in Schedule 4.12
hereto and is not in receipt of any claim of default under any contract or
commitment required to be disclosed under such caption; Atlantic and each
Atlantic Subsidiary, where applicable, have no present expectation or intention
of not fully performing any material obligation pursuant to any contract or
commitment required to be disclosed under such caption; and Atlantic has no
Knowledge of any breach or anticipated breach by any other party to any contract
or commitment required to be disclosed under such caption.
4.13 Intellectual Property.
(a) Except as set forth in Schedule 4.13(a), Atlantic owns or has
licenses to use all of the following used in or necessary to conduct its
business as currently conducted (collectively, the "Atlantic Intellectual
Property"): (i) Patents; (ii) Copyrights; (iii) Trademarks; (iv) Know-How; and
(v) software.
24
(b) Set forth on Schedule 4.13(b) is a complete and accurate list of
all Patents, Trademarks, registered or material Copyrights and Software owned or
licensed by Atlantic. Schedule 4.13(b) sets forth a complete and accurate list
of all Persons from which or to which Atlantic licenses any material
Intellectual Property.
(c) Atlantic is the sole and exclusive owner of the Atlantic
Intellectual Property its purports to own, free and clear of all liens and
encumbrances and free of all licenses except those set forth in Schedule 4.13(c)
and licenses relating to off-the-shelf software having a per-application
acquisition price of less than $5,000. No Copyright registration, Trademark
registration, or Patent set forth in Schedule 4.13(b) has lapsed, expired or
been abandoned or cancelled, or is subject to any pending or, to Atlantic's
Knowledge, threatened opposition or cancellation proceeding in any country.
(d) Except as set forth in Schedule 4.13(d), to Atlantic's Knowledge
(1) neither the conduct of Atlantic's business nor the manufacture, marketing,
licensing, sale, distribution or use of its products or services infringes upon
the proprietary rights of any Person, and (2) there are no infringements of the
Atlantic Intellectual Property by any Person. Except as set forth in Schedule
4.13(a) and Schedule 4.13(c), there are no claims pending or, to Atlantic's
Knowledge, threatened (1) alleging that Atlantic's business as currently
conducted infringes upon or constitutes an unauthorized use or violation of the
proprietary rights of any Person, or (2) alleging that the Atlantic Intellectual
Property is being infringed by any Person, or (3) challenging the ownership,
validity or enforceability of the Atlantic Intellectual Property.
(e) Atlantic has not entered into any consent agreement,
indemnification agreement, forbearance to sue, settlement agreement or
cross-licensing arrangement with any Person relating to the Atlantic
Intellectual Property other than as part of the license agreements listed in
Schedule 4.13(b) or set forth in Schedule 4.13(c).
(f) Except as set forth in Schedule 4.13(f), Atlantic is not, nor
will it be as a result of the execution and delivery of this Agreement or the
performance of its obligations under this Agreement, in breach of any license,
sublicense or other Contract relating to the Atlantic Intellectual Property that
would reasonably be expected, individually or in the aggregate, to have a
Material Adverse Effect on Atlantic.
4.14 Employee Benefit Plans.
(a) Schedule 4.14(a) lists all material (i) "employee benefit
plans," within the meaning of Section 3(3) of ERISA, of Atlantic, (ii) bonus,
stock option, stock purchase, stock appreciation right, incentive, deferred
compensation, supplemental retirement, severance, and fringe benefit plans,
programs, policies or arrangements, and (iii) employment or consulting
agreements, for the benefit of, or relating to, any current or former employee
(or any beneficiary thereof) of Atlantic, in the case of a plan described in (i)
or (ii) above, that is currently maintained by Atlantic or with respect to which
Atlantic has an obligation to contribute, and in the case of an agreement
described in (iii) above, that is currently in effect (the "Atlantic Plans").
Atlantic has heretofore made available to Manhattan true and complete copies of
the Atlantic Plans and any amendments thereto, any related trust, insurance
contract, summary plan
25
description, and, to the extent required under ERISA or the Code, the most
recent annual report on Form 5500 and summaries of material modifications.
(b) No Atlantic Plan is (1) a "multiemployer plan" within the
meaning of Sections 3(37) or 4001(a)(3) of ERISA, (2) a "multiple employer plan"
within the meaning of Section 3(40) of ERISA or Section 413(c) of the Code, or
(3) is subject to Title IV of ERISA or Section 412 of the Code.
(c) Except as set forth in Schedule 4.14(c), there is no proceeding
pending or, to Atlantic's Knowledge, threatened against the assets of any
Atlantic Plan or, with respect to any Atlantic Plan, against Atlantic other than
proceedings that would not reasonably be expected to result in a material
liability, and to Atlantic's Knowledge there is no proceeding pending or
threatened in writing against any fiduciary of any Atlantic Plan other than
proceedings that would not reasonably be expected to result in a material
liability.
(d) Each of the Atlantic Plans has been operated and administered
in all material respects in accordance with its terms and applicable law,
including, but not limited to, ERISA and the Code.
(e) Each of the Atlantic Plans that is intended to be "qualified"
within the meaning of Section 401(a) of the Code has received a favorable
determination, notification, or opinion letter from the IRS.
(f) Except as set forth in Schedule 4.14(f), no director, officer,
or employee of Atlantic will become entitled to retirement, severance or similar
benefits or to enhanced or accelerated benefits (including any acceleration of
vesting or lapsing of restrictions with respect to equity-based awards) under
any Atlantic Plan solely as a result of consummation of the transactions
contemplated by this Agreement.
4.15 Employees.
(a) Schedule 4.15 lists the following information for each employee
and each director of Atlantic as of the date of this Agreement, including each
employee on leave of absence or layoff status: (1) name; (2) job title; (3)
current annual base salary or annualized wages; (4) bonus compensation earned
during 2001; (5) vacation accrued and unused; (6) service credited for purposes
of vesting and eligibility to participate under Manhattan Plans; and (7) the
number of shares of Atlantic Common Stock beneficially owned by each such
employee.
(b) Except as otherwise set forth in Schedule 4.15, or as
contemplated by this Agreement, to the Knowledge of Atlantic, neither any
executive employee of Atlantic nor any group of Atlantic's employees has any
plans to terminate his, her or its employment; (b) Atlantic has no material
labor relations problem pending and its labor relations are satisfactory; (c)
there are no workers' compensation claims pending against Atlantic nor is
Atlantic aware of any facts that would give rise to such a claim; (d) to the
Knowledge of Atlantic, no employee of Atlantic is subject to any secrecy or
noncompetition agreement or any other agreement or restriction of any kind that
would impede in any way the ability of such employee to carry out fully all
activities of such employee in furtherance of the business of Atlantic; and (f)
no employee or former
26
employee of Atlantic has any claim with respect to any intellectual property
rights of Atlantic set forth in Schedule 4.13 hereto.
4.16 Affiliate Transactions. Except as set forth in Schedule 4.16 hereto,
and other than pursuant to this Agreement, no officer, director or employee of
Atlantic, any Atlantic Subsidiary or any member of the immediate family of any
such officer, director or employee, or any entity in which any of such persons
owns any beneficial interest (other than any publicly-held corporation whose
stock is traded on a national securities exchange or in the over-the-counter
market and less than one percent of the stock of which is beneficially owned by
any of such persons) (collectively "Atlantic Insiders"), has any agreement with
Atlantic (other than normal employment arrangements) or any interest in any
property, real, personal or mixed, tangible or intangible, used in or pertaining
to the business of Atlantic (other than ownership of capital stock of Atlantic).
Atlantic is not indebted to any Atlantic Insider (except for amounts due as
normal salaries and bonuses and in reimbursement of ordinary business expenses)
and no Atlantic Insider is indebted to Atlantic) except for cash advances for
ordinary business expenses). None of the insiders has any direct or indirect
interest in any competitor, supplier or customer of Atlantic or in any person,
firm or entity from whom or to whom Atlantic leases any property, or in any
other person, firm or entity with whom Atlantic transacts business of any
nature. For purposes of this Section 4.16, the members of the immediate family
of an officer, director or employee shall consist of the spouse, parents and
children of such officer, director or employee.
4.17 Compliance with Laws; Permits.
(a) Except for any noncompliance that would not reasonably be
expected to have a Material Adverse Effect on Atlantic, Atlantic, each Atlantic
Subsidiary and their respective officers, directors, agents and employees have
complied with all applicable laws, regulations and other requirements,
including, but not limited to, federal, state, local and foreign laws,
ordinances, rules, regulations and other requirements pertaining to equal
employment opportunity, employee retirement, affirmative action and other hiring
practices, occupational safety and health, workers' compensation, unemployment
and building and zoning codes, and no claims have been filed against Atlantic,
and Atlantic has not received any notice, alleging a violation of any such laws,
regulations or other requirements. Atlantic is not relying on any exemption from
or deferral of any such applicable law, regulation or other requirement that
would not be available to Manhattan after it acquires Atlantic's properties,
assets and business.
(b) Each of Atlantic and the Atlantic Subsidiaries has, in full
force and effect, all licenses, permits and certificates from federal, state,
local and foreign authorities (including, without limitation, federal and state
agencies regulating occupational health and safety) necessary to permit it to
conduct its business and own and operate its properties (collectively, the
"Atlantic Permits"). A complete list of all the Permits is set forth in Schedule
4.17 hereto. Each of Atlantic and the Atlantic Subsidiaries has conducted its
business in compliance with terms and conditions of the Atlantic Permits.
4.18 Books and Records. The books of account, minute books, stock record
books, and other records of Atlantic, all of which have been made available to
Manhattan, have been properly kept and contain no inaccuracies except for
inaccuracies that would not, individually or
27
in the aggregate, reasonably be expected to have a Material Adverse Effect on
Atlantic. At the Closing, all of Atlantic's records will be in the possession of
Atlantic.
4.19 Real Property. Neither Atlantic nor any Atlantic Subsidiary owns any
real property. Schedule 4.19 contains an accurate list of all leaseholds and
other interests of Atlantic any each Atlantic Subsidiary in any real property.
Atlantic and such Atlantic Subsidiaries have good and valid title to those
leaseholds and other interests free and clear of all liens and encumbrances, and
the real property to which those leasehold and other interests pertain
constitutes the only real property used in Atlantic's business.
4.20 Insurance. The insurance policies owned and maintained by Atlantic
that are material to Atlantic are in full force and effect, all premiums due and
payable thereon have been paid (other than retroactive or retrospective premium
adjustments that Atlantic is not currently required, but may in the future be
required, to pay with respect to any period ending prior to the date of this
Agreement), and Atlantic has received no notice of cancellation or termination
with respect to any such policy that has not been replaced on substantially
similar terms prior to the date of such cancellation.
4.21 Environmental Matters. None of the operations of Atlantic or any
Atlantic Subsidiary involves the generation, transportation, treatment, storage
or disposal of hazardous waste, as defined under 40 C.F.R. Parts 260-270 or any
state, local or foreign equivalent.
4.22 Proprietary Information and Inventions. Each current Atlantic
employee, consultant, and advisory board member is party to either a
non-disclosure agreement in the form attached as Schedule 4.22 or an alternative
employment agreement with Atlantic containing comparable non-disclosure
provisions. To Atlantic's Knowledge, no current or former Atlantic employee,
consultant or advisory board member who is party to a non-disclosure agreement
has breached that non-disclosure agreement. To Atlantic's Knowledge, no current
Atlantic employee, consultant or advisory board member who is party to an
alternative employment agreement with Atlantic has breached the non-disclosure
provisions of that agreement.
4.23 Vote Required. The affirmative vote of a majority of the votes that
holders of the outstanding shares of Atlantic Common Stock and Series A
convertible preferred stock of Atlantic, voting together as one class, are
entitled to cast is the only vote of the holders of any class or series of
Atlantic capital stock necessary to approve the matters to be considered at the
Atlantic Stockholders Meeting.
4.24 Tax Free Reorganization. Neither Atlantic nor, to Atlantic's
Knowledge, any of its Affiliates has through the date of this Agreement taken or
agreed to take any action that would prevent the Merger from qualifying as a
reorganization under Section 368(a) of the Code.
4.25 Full Disclosure. The representations and warranties of Atlantic and
MPAC contained in this Agreement (and in any schedule, exhibit, certificate or
other instrument to be delivered under this Agreement) are true and correct in
all material respects, and such representations and warranties do not omit any
material fact necessary to make the statements contained therein, in light of
the circumstances under which they were made, not misleading.
28
There is no fact of which Atlantic or MPAC has Knowledge that has not been
disclosed to Manhattan pursuant to this Agreement, including the schedules
hereto, all taken together as a whole, which has had or could reasonably be
expected to have a Material Adverse Effect on Atlantic or MPAC, or materially
adversely affect the ability of Atlantic or MPAC to consummate in a timely
manner the transactions contemplated hereby.
ARTICLE V
CONDUCT OF BUSINESS PENDING THE MERGER
5.1 Conduct of Business by Atlantic. From the date of this Agreement to
the Effective Date, unless Manhattan shall otherwise agree in writing or as
otherwise expressly contemplated or permitted by other provisions of this
Agreement, including but not limited to this Section 5.1, Atlantic shall not,
directly or indirectly, (a) amend its Certificate of Incorporation or Bylaws,
except as set forth on Schedule 5.1, (b) split, combine or reclassify any
outstanding shares of capital stock of Atlantic, (c) declare, set aside, make or
pay any dividend or distribution in cash, stock, property or otherwise with
respect to the capital stock of Atlantic, (d) default in its obligations under
any material debt, contract or commitment which default results in the
acceleration of obligations due thereunder, except for such defaults arising out
of Atlantic's entry into this Agreement for which consents, waivers or
modifications are required to be obtained as set forth on Schedule 4.2, (e)
conduct its business other than in the ordinary course on an arms-length basis
and in accordance in all material respects with all applicable laws, rules and
regulations and Atlantic's past custom and practice (except that Atlantic may
license its rights to the NCT technologies and transfer its shares of stock in
CryoComm, Inc. to Persons wholly or partially owned by one or more Atlantic
directors or officers in return for a 10% share of any royalty, milestone or
other revenues generated by the NCT technologies and shares of CryoComm, Inc.),
(f) issue or sell any additional shares of, or options, warrants, conversions,
privileges or rights of any kind to acquire any shares of, any of its capital
stock, except as otherwise set forth in Schedule 5.1 hereto or in connection
with the exercise or conversion of Atlantic securities outstanding on the date
of this Agreement or payment of stock dividends on Atlantic's Series A
convertible preferred stock in accordance with the terms of the certificate of
designation of Atlantic's Series A convertible preferred stock, (g) acquire (by
merger, exchange, consolidation, acquisition of stock or assets or otherwise)
any corporation, partnership, joint venture or other business organization or
division or material assets thereof or (h) make or change any material tax
elections, settle or compromise any material tax liability or file any amended
tax return.
5.2 Conduct of Business by Manhattan. From the date of this Agreement to
the Effective Date, unless Atlantic shall otherwise agree in writing or as
otherwise expressly contemplated or permitted by other provisions of this
Agreement, including but not limited to this Section 5.2, Manhattan shall not,
directly or indirectly, (a) amend its Certificate of Incorporation or Bylaws,
(b) split, combine or reclassify any outstanding shares of capital stock of
Manhattan, (c) declare, set aside, make or pay any dividend or distribution in
cash, stock, property or otherwise with respect to the capital stock of
Manhattan, (d) default in its obligations under any material debt, contract or
commitment which default results in the acceleration of obligations due
thereunder, except for such defaults arising out of Manhattan's entry into this
Agreement for which consents, waivers or modifications are required to be
obtained as set forth on Schedule 3.2, (e) conduct its business other than in
the ordinary course on an arms-length
29
basis and in accordance in all material respects with all applicable laws, rules
and regulations and Manhattan's past custom and practice, (f) issue or sell any
additional shares of, or options, warrants, conversions, privileges or rights of
any kind to acquire any shares of, any of its capital stock, except as otherwise
described on Schedule 5.2 hereto or in connection with exercise or conversion of
Manhattan securities outstanding on the date of this Agreement, (g) acquire (by
merger, exchange, consolidation, acquisition of stock or assets or otherwise)
any corporation, partnership, joint venture or other business organization or
division or material assets thereof or (h) make or change any material tax
elections, settle or compromise any material tax liability or file any amended
tax return.
ARTICLE VI
ADDITIONAL COVENANTS AND AGREEMENTS
6.1 Governmental Filings. Each party will use all reasonable efforts and
will cooperate with the other party in the preparation and filing, as soon as
practicable, of all filings, applications or other documents required under
applicable laws, including, but not limited to, the Exchange Act, to consummate
the transactions contemplated by this Agreement. Prior to submitting each
filing, application, registration statement or other document with the
applicable regulatory authority, each party will, to the extent practicable,
provide the other party with an opportunity to review and comment on each such
application, registration statement or other document to the extent permitted by
applicable law. Each party will use all reasonable efforts and will cooperate
with the other party in taking any other actions necessary to obtain such
regulatory or other approvals and consents at the earliest practicable time,
including participating in any required hearings or proceedings. Subject to the
terms and conditions herein provided, each party will use all reasonable efforts
to take, or cause to be taken, all actions and to do, or cause to be done, all
things necessary, proper or advisable to consummate and make effective as
promptly as practicable the transactions contemplated by this Agreement.
6.2 Expenses. Except as otherwise provided in this Agreement, all costs
and expenses incurred in connection with this Agreement and the transactions
contemplated hereby shall be paid by the party incurring such costs and
expenses.
6.3 Due Diligence; Access to Information; Confidentiality.
(a) Between the date hereof and the date of filing the Proxy Statement
with the SEC, Manhattan and Atlantic shall afford to the other party and their
authorized representatives the opportunity to conduct and complete a due
diligence investigation of the other party as described herein. In light of the
foregoing, each party shall permit the other party full access on reasonable
notice and at reasonable hours to its properties and shall disclose and make
available (together with the right to copy) to the other party and its officers,
employees, attorneys, accountants and other representatives, all books, papers
and records relating to the assets, stock, properties, operations, obligations
and liabilities of such party and its subsidiaries, including, without
limitation, all books of account (including, without limitation, the general
ledger), tax records, minute books of directors' and stockholders' meetings,
organizational documents, bylaws, contracts and agreements, filings with any
regulatory authority, accountants' work papers, litigation files (including,
without limitation, legal research memoranda), attorney's audit response
letters, documents relating to assets and title thereto (including, without
limitation,
30
abstracts, title insurance policies, surveys, environmental reports, opinions of
title and other information relating to the real and personal property), plans
affecting employees, securities transfer records and stockholder lists, and any
books, papers and records relating to other assets or business activities in
which such party may have a reasonable interest, and otherwise provide such
assistance as is reasonably requested in order that each party may have a full
opportunity to make such investigation and evaluation as it shall reasonably
desire to make of the business and affairs of the other party; provided,
however, that the foregoing rights granted to each party shall, whether or not
and regardless of the extent to which the same are exercised, in no way affect
the nature or scope of the representations, warranties and covenants of the
respective party set forth herein. In addition, each party and its officers and
directors shall cooperate fully (including providing introductions, where
necessary) with such other party to enable the party to contact third parties,
including customers, prospective customers, specified agencies or others as the
party deems reasonably necessary to complete its due diligence; provided that
such party agrees not to initiate such contacts without the prior approval of
the other party, which approval will not be unreasonably withheld.
(b) Either Atlantic or Manhattan may, in its sole discretion, elect not to
proceed with the Merger based upon its due diligence investigation performed
pursuant to Section 6.3(a) above, if the results of such due diligence
investigation, in Atlantic's or Manhattan's reasonable judgment, reveals any
event, condition or occurrence (not previously disclosed in this Agreement or
the schedules attached hereto) that would reasonably be expected to have a
Material Adverse Effect on the other party, by providing such other party with
written notice thereof on or before the date of the Proxy Statement.
(c) Prior to Closing and if, for any reason, the transactions contemplated
by this Agreement are not consummated, neither Atlantic nor Manhattan nor any of
their officers, employees, attorneys, accountants and other representatives
shall disclose to third parties or otherwise use any confidential information
received from the other party in the course of investigating, negotiating, and
performing the transactions contemplated by this Agreement; provided, however,
that nothing shall be deemed to be confidential information which:
(i) is known to the party receiving the information at the time of
disclosure, unless any individual who knows the information is
under an obligation to keep that information confidential;
(ii) becomes publicly known or available without the disclosure
thereof by the party receiving the information in violation of
this Agreement; or
(iii) is received by the party receiving the information from a
third party not under an obligation to keep that information
confidential.
This provision shall not prohibit the disclosure of information required to be
made under federal or state securities laws. If any disclosure is so required,
the party making such disclosure shall consult with the other party prior to
making such disclosure, and the parties shall use all reasonable efforts, acting
in good faith, to agree upon a text for such disclosure which is satisfactory to
both parties.
31
6.4 Proxy Statement.
(a) In connection with the solicitation of proxies for the Atlantic
Stockholder Meeting, the parties hereto shall cooperate in the preparation of an
appropriate proxy statement (such proxy statement, together with any and all
amendments or supplements thereto, being herein referred to as the "Proxy
Statement").
(b) Manhattan shall furnish such information concerning Manhattan as
is necessary in order to cause the Proxy Statement, insofar as it relates to
Manhattan and Manhattan securities, to be prepared in accordance with Section
6.4(a). Manhattan shall also furnish to Atlantic, for purposes of its
preparation of the Proxy Statement in accordance with Section 6.4(a), any
required information regarding any Manhattan stockholders or Affiliates or any
Manhattan nominees to Atlantic's board of directors. That information must be
true and correct in all material respects and must not omit any material fact
necessary to make that information not misleading. Manhattan agrees promptly to
advise Atlantic if at any time prior to the Atlantic Stockholders Meeting any
information provided by Manhattan in the Proxy Statement becomes incorrect or
incomplete in any material respect, and to provide Atlantic the information
needed to correct such inaccuracy or omission.
(c) Atlantic shall use all reasonable efforts to promptly prepare
and submit the Proxy Statement to the SEC. Atlantic shall use reasonable efforts
to file the definitive Proxy Statement at the earliest practicable date.
Atlantic agrees to provide Manhattan and its counsel with reasonable opportunity
to review and comment on the Proxy Statement and any amendment thereto before
filing with the SEC or any other governmental entity and agrees not to make such
filing if Manhattan and its counsel reasonably object to the completeness or
accuracy of any information contained therein. Manhattan authorizes Atlantic to
utilize in the Proxy Statement the information under Section 6.4(a) provided to
Atlantic for the purpose of inclusion in the Proxy Statement. Atlantic shall
advise Manhattan promptly when the definitive Proxy Statement has been filed and
shall furnish Manhattan with copies of all such documents.
(d) At the time the Proxy Statement is mailed to the stockholders of
Atlantic in order to obtain the Requisite Atlantic Stockholder Votes and at all
times subsequent to such mailing until the Requisite Atlantic Stockholder Votes
have been obtained, the Proxy Statement (including any amendments or supplements
thereto), with respect to all information set forth therein relating to Atlantic
and its stockholders, this Agreement, the Certificate of Merger, and all other
transactions contemplated hereby, will (i) comply in all material respects with
applicable provisions of the Exchange Act, including the rules and regulations
promulgated thereunder, and (ii) not contain any untrue statement of material
fact or omit to state a material fact required to be stated therein or necessary
to make the statements contained therein, in light of the circumstances under
which they are made, not misleading, except that, in each case, no such
representations shall apply to any written information, including financial
statements, of or provided by Manhattan for such Proxy Statement.
(e) Atlantic shall bear all printing and mailing costs in connection
with the preparation and mailing of the Proxy Statement to Atlantic
stockholders. Manhattan and Atlantic shall each bear their own legal and
accounting expenses in connection with the Proxy Statement.
32
6.5 Tax Treatment. None of Atlantic, MPAC or Manhattan, or the Surviving
Company after the Effective Date, shall knowingly take any action which could
reasonably be expected to disqualify the Merger as a "reorganization" within the
meaning of Section 368(a) of the Code.
6.6 Press Releases. Manhattan and Atlantic shall agree with each other as
to the form and substance of any press release or public announcement related to
this Agreement or the transactions contemplated hereby; provided, however, that
nothing contained herein shall prohibit either party, following notification to
the other party, from making any disclosure which is required by law or
regulation. If any such press release or public announcement is so required, the
party making such disclosure shall consult with the other party prior to making
such disclosure, and the parties shall use all reasonable efforts, acting in
good faith, to agree upon a text for such disclosure which is satisfactory to
both parties.
6.7 Securities Reports. Atlantic agrees to provide to Manhattan copies of
all reports and other documents filed under the Securities Act or Exchange Act
with the SEC by it between the date hereof and the Effective Date within two (2)
days after the date such reports or other documents are filed with the SEC.
6.8 Private Placement. Each of Manhattan and Atlantic shall take all
necessary action on its part such that the issuance of the Merger Consideration
to Manhattan stockholders constitutes a valid "private placement" under the
Securities Act. Without limiting the generality of the foregoing, Manhattan
shall (1) provide each Manhattan stockholder with a stockholder qualification
questionnaire in the form reasonably acceptable to both Atlantic and Manhattan
(a "Stockholder Questionnaire") and (2) use its best efforts to cause each
Manhattan stockholder to attest that that stockholder either (A) is an
"accredited investor" as defined in Regulation D of the Securities Act, (B) has
such knowledge and experience in financial and business matters that the
stockholder is capable of evaluating the merits and risks of receiving the
Merger Consideration, or (C) has appointed an appropriate person reasonably
acceptable to both Atlantic and Manhattan to act as the stockholder's purchaser
representative in connection with evaluating the merits and risks of receiving
the Merger Consideration.
6.9 Stockholder Approvals. Atlantic shall call a meeting of its
stockholders (the "Atlantic Stockholder Meeting") for the purpose of obtaining
approval of (a) an increase in the number of authorized shares of Atlantic
Common Stock so as to permit Atlantic to issue the Merger Consideration and (b)
amendment of the certificate of designations of the Series A convertible
preferred stock of Atlantic to provide for mandatory conversion immediately
prior to the Effective Time of all outstanding shares of Series A convertible
preferred stock of Atlantic (the "Atlantic Proposals"). Such meeting shall be
held as soon as practicable following the date of this Agreement, but in no
event later than February 7, 2003. The Board of Directors of Atlantic and
Manhattan shall recommend approval of this Agreement and the Merger and use all
reasonable efforts (including, without limitation, soliciting proxies for such
approvals) to obtain approvals thereof from its stockholders; provided, however,
either party's Board of Directors may fail to make such recommendation, and/or
to seek to obtain the stockholder approval referred to in this sentence, or
withdraw, modify or change any such recommendation, if such Board of Directors
determines, in good faith, after consultation with counsel, that the making of
such recommendation, the seeking to obtain such stockholder approval, or the
failure to so
33
withdraw, modify or change its recommendation, may constitute a breach of the
fiduciary or legal obligations of such Board of Directors.
6.10 Manhattan Stockholders' Meeting; Materials to Stockholders.
(a) Manhattan shall, in accordance with Section 251 of the DGCL and
its certificate of incorporation and by-laws, duly call, give notice of, convene
and hold a special meeting of Manhattan Stockholders (the "Manhattan Stockholder
Meeting") as promptly as practicable after the date hereof for the purpose of
considering and taking action upon this Agreement and the Merger. In addition,
Manhattan shall use its best efforts to obtain, prior to the Manhattan
Stockholder Meeting, unanimous written consent of Manhattan stockholders
approving this Agreement and the Merger.
(b) Manhattan shall as promptly as practicable following the date of
this Agreement prepare and mail to Manhattan stockholders all information as may
required to comply with the DGCL, the Securities Act and the Exchange Act.
6.11 No Solicitation.
(a) Unless and until this Agreement shall have been terminated
pursuant to Section 8.1, neither Atlantic nor its officers, directors or agents
shall, directly or indirectly, encourage, solicit or initiate discussions or
negotiations with, or engage in negotiations or discussions with, or provide
non-public information to, any corporation, partnership, person or other entity
or groups concerning any merger, sale of capital stock, sale of substantial
assets or other business combination; provided that Atlantic may engage in such
discussion in response to an unsolicited proposal from an unrelated party if the
Board of Directors of Atlantic determines, in good faith, after consultation
with counsel, that the failure to engage in such discussions may constitute a
breach of the fiduciary or legal obligations of the Board of Directors of
Atlantic. Atlantic will promptly advise Manhattan if it receives a proposal or
inquiry with respect to the matters described above.
(b) Unless and until this Agreement shall have been terminated
pursuant to Section 8.1, neither Manhattan nor its officers, directors or agents
shall, directly or indirectly, encourage, solicit or initiate discussions or
negotiations with, or engage in negotiations or discussions with, or provide
non-public information to, any corporation, partnership, person or other entity
or groups concerning any merger, sale of capital stock, sale of substantial
assets or other business combination; provided that Manhattan may engage in such
discussion in response to any unsolicited proposal from an unrelated party if
the Board of Directors of Manhattan determines, in good faith, after
consultation with counsel, that the failure to engage in such discussions may
constitute a breach of the fiduciary or legal obligations of the Board of
Directors of Manhattan. Manhattan will promptly advise Atlantic if it receives a
proposal or inquiry with respect to the matters described above.
6.12 Failure to Fulfill Conditions. In the event that either of the
parties hereto determines that a condition to its respective obligations to
consummate the transactions contemplated hereby cannot be fulfilled on or prior
to the termination of this Agreement, it will promptly notify the other party.
34
6.13 Tax Opinion. Manhattan and Atlantic shall make such representations,
warranties and covenants as are reasonably requested by Maslon Edelman Borman &
Brand, LLP in order for it to render the tax opinion contemplated by Section
7.1(c).
6.14 Resignations and Election of Directors. Before the Effective Time,
Atlantic shall deliver the voluntary resignations of each officer of Atlantic
and each director of Atlantic not continuing to serve in that capacity following
the Effective Time. Such resignations shall be effective upon the Effective
Time. Immediately after the Effective Time, the remaining director(s) of
Atlantic shall appoint the persons identified in Section 2.7 to serve as
directors of Atlantic following the Effective Time.
6.15 Rule 144 Reporting and Rule 144. With a view to making it possible
for holders of shares of Atlantic Common Stock received in the Merger to sell
those shares under Rule 144 promulgated under the Securities Act ("Rule 144"),
Atlantic shall use commercially reasonable efforts to (1) make and keep
available current public information, as defined in Rule 144, (2) timely file
with the SEC all reports and other documents required to be filed by Atlantic
under the Securities Act and the Exchange Act, and (3) comply with all rules and
regulations of the SEC applicable in connection with the use of Rule 144 and
take such other actions and furnish each holder of shares of Atlantic Common
Stock received in the Merger with such other information as that holder
reasonably requests in order to avail itself of Rule 144.
6.16 Registration Rights.
(a) Subject to reasonable and customary black-out periods in the
case of certain public offerings by Atlantic as may be requested by the managing
underwriter in connection with such offerings (but in no event more than one
hundred eighty (180) days during any twelve month period), upon receipt of a
written request of holders of at least fifty percent (50%) of the Atlantic
Common Stock issued by Atlantic under this Agreement and unregistered through
the date of such request (the "Registrable Securities"), Atlantic shall use its
reasonable best efforts, at its own expense (excluding underwriting commissions
and discounts) for one demand, to file within thirty (30) days from the date of
such written notice, a registration statement with the SEC under the Securities
Act registering the Registrable Securities for public resale (the "Demand
Registration Statement") and shall use its best efforts to have such
registration statement declared effective by the SEC; provided, however, that
the registration rights granted under this Section shall not be assignable by
the stockholders of Manhattan immediately prior to the Effective Time, except
for transfers to family trusts or controlled Affiliates. Atlantic is not
required to maintain the effectiveness of any Demand Registration Statement
required to be filed in accordance with this paragraph (a) beyond the period
ending on the earlier of the following dates: (i) the date one year after the
effective date of the Demand Registration Statement; and (ii) the date on which
all Registrable Securities covered by the Demand Registration Statement have
been sold and the distribution thereby has been completed.
(b) If at any time prior to the first anniversary of the Effective
Date, Atlantic proposes to register under the Securities Act (except by a Form
S-4 or Form S-8 Registration Statement or any successor forms thereto or a
registration statement covering only (1) an employee stock option, stock
purchase or compensation plan or securities issued or issuable pursuant to any
such plan, or (2) a dividend reinvestment plan) or qualify for a public
35
distribution under Section 3(b) of the Securities Act, any of its equity
securities or debt with equity features (other than in accordance with Section
6.16(a)), it will give written notice to all holders of the Registrable
Securities of its intention to do so and, on the written request of the holders
of at least fifty percent (50%) of the Registrable Securities received within
twenty (20) after receipt of any such notice, Atlantic will use its best efforts
to cause all of the Registrable Securities to be included in such registration
statement proposed to be filed by Atlantic; provided, however, that nothing
herein shall prevent Atlantic from, at any time, abandoning or delaying any
registration. The right of the holders of the Registrable Securities to include
the such securities in any such registration statement may be subject to
approval by selling securityholders whose securities are being registered in the
registration statement. If any registration pursuant to this Section 6.16(b) is
underwritten in whole or in part, Atlantic may require that the Registrable
Securities be included in the underwriting on the same terms and conditions as
the securities otherwise being sold through the underwriters and each holder of
Registrable Securities shall execute any underwriting agreement, "lock-up"
letters or other customary agreements or documents executed by Atlantic in
connection with that underwritten offering. If, in the reasonable opinion of the
managing underwriter of the proposed offering, the number of Registrable
Securities offered for participation in the proposed offering cannot be
accommodated without adversely affecting the proposed offering, then the amount
of Registrable Securities proposed to be offered, as well as the number of
securities of any other selling stockholders participating in the registration
(other than holders of Registrable Securities being registered in accordance
with Section 6.16(a)), shall be proportionately reduced to a number deemed
satisfactory by the managing underwriter.
6.17 Notification of Certain Matters. On or prior to the Effective Date,
each party shall give prompt notice to the other party of (i) the occurrence or
failure to occur of any event or the discovery of any information, which
occurrence, failure or discovery would be likely to cause any representation or
warranty on its part contained in this Agreement to be untrue, inaccurate or
incomplete after the date hereof in any material respect or, in the case of any
representation or warranty given as of a specific date, would be likely to cause
any such representation or warranty on its part contained in this Agreement to
be untrue, inaccurate or incomplete in any material respect as of such specific
date, and (ii) any material failure of such party to comply with or satisfy any
covenant or agreement to be complied with or satisfied by it hereunder.
ARTICLE VII
CONDITIONS
7.1 Conditions to Obligations of Each Party. The respective obligations of
each party to effect the transactions contemplated hereby are subject to the
fulfillment or waiver at or prior to the Effective Date of the following
conditions:
(a) No Prohibitive Change of Law. There shall have been no law,
statute, rule or regulation, domestic or foreign, enacted or promulgated which
would prohibit or make illegal the consummation of the transactions contemplated
hereby.
36
(b) Federal Tax Opinion. Manhattan shall have received from Maslon
Edelman Borman & Brand, LLP a tax opinion dated as of the Closing Date to the
effect that for federal income tax purposes:
(i) The Merger will qualify as a reorganization under Section
368(a) of the Code. Atlantic and Manhattan will each be a party to
the reorganization within the meaning of Section 368(b) of the Code.
(ii) No gain or loss will be recognized by stockholders of
Manhattan upon the receipt of the Merger Consideration.
(c) Stockholder Approvals. This Agreement and the Merger shall have
been approved by the Requisite Manhattan Stockholder Vote and the Atlantic
Proposals shall have been approved by the Requisite Atlantic Stockholder Votes.
(d) Adverse Proceedings. There shall not be threatened, instituted
or pending any action or proceeding before any court or governmental authority
or agency (i) challenging or seeking to make illegal, or to delay or otherwise
directly or indirectly restrain or prohibit, the consummation of the
transactions contemplated hereby or seeking to obtain material damages in
connection with such transactions, (ii) seeking to prohibit direct or indirect
ownership or operation by Atlantic or MPAC of all or a material portion of the
business or assets of Manhattan, or to compel Atlantic or MPAC or any of their
respective subsidiaries or Manhattan to dispose of or to hold separately all or
a material portion of the business or assets of Atlantic or any Atlantic
Subsidiary or of Manhattan, as a result of the transactions contemplated hereby;
(iii) seeking to invalidate or render unenforceable any material provision of
this Agreement or any of the other agreements attached as exhibits hereto or
contemplated hereby, or (iv) otherwise relating to and materially adversely
affecting the transactions contemplated hereby.
(e) Governmental Action. There shall not be any action taken, or any
statute, rule, regulation, judgment, order or injunction proposed, enacted,
entered, enforced, promulgated, issued or deemed applicable to the transactions
contemplated hereby, by any federal, state or other court, government or
governmental authority or agency, that would reasonably be expected to result,
directly or indirectly, in any of the consequences referred to in Section
7.1(d).
(f) Market Condition. There shall not have occurred any general
suspension of trading on the New York Stock Exchange, the Nasdaq Stock Markets,
or any suspension of trading in Atlantic Common Stock, or any general bank
moratorium or closing or any war, national emergency or other event affecting
the economy or securities trading markets generally that would make completion
of the Merger impossible.
(g) Conversion of Preferred Stock. Immediately prior to the
Effective Time all shares of Series A convertible preferred stock of Atlantic
shall have been converted into shares of Atlantic Common Stock, as contemplated
by the applicable Atlantic Proposal.
(h) Amendment of Employment Agreements. Atlantic shall have entered
into amended employment agreements with Frederic P. Zotos, Nicholas J.
Rossettos, A. Joseph Rudick, Michael Ferrari, and Sarah Laut, the terms of which
shall be subject to the consent of
37
Manhattan, which shall not be unreasonably withheld. Such amended agreements
shall provide that one-half of the deferred salary and accrued bonus payable to
each such employee upon the termination of his or her employment by Atlantic
without cause shall be paid at such time that Atlantic has received aggregate
cash funds of $3 million from financings or other sources on or after the
Effective Time; and the remaining one-half of the deferred salary and accrued
bonus shall be paid at such time as Atlantic has received aggregate cash funds
of $6 million from financings or other sources on or after the Effective Time.
(i) Manhattan Available Capital. Manhattan shall have at least
$500,000 in cash (or cash equivalents) available to the Surviving Company.
7.2 Additional Conditions to Obligation of Atlantic and MPAC. The
obligation of Atlantic and MPAC to consummate the transactions contemplated
hereby in accordance with the terms of this Agreement is also subject to the
fulfillment or waiver of the following conditions:
(a) Representations and Compliance. The representations of Manhattan
contained in this Agreement were accurate as of the date of this Agreement and
are accurate as of the Effective Time, in all respects (in the case of any
representation containing any materiality qualification) or in all material
respects (in the case of any representation without any materiality
qualification). Manhattan shall in all material respects have performed each
obligation and agreement and complied with each covenant to be performed and
complied with by it hereunder at or prior to the Effective Date.
(b) Officers' Certificate. Manhattan shall have furnished to
Atlantic a certificate of the Chief Executive Officer and the Treasurer of
Manhattan, dated as of the Effective Date, in which such officers shall certify
that, to their best Knowledge, the conditions set forth in Section 7.2(a) have
been fulfilled.
(c) Secretary's Certificate. Manhattan shall have furnished to
Atlantic (i) copies of the text of the resolutions by which the corporate action
on the part of Manhattan necessary to approve this Agreement, the Certificate of
Merger and the transactions contemplated hereby and thereby were taken, (ii) a
certificate dated as of the Effective Date executed on behalf of Manhattan by
its corporate secretary or one of its assistant corporate secretaries certifying
to Atlantic that such copies are true, correct and complete copies of such
resolutions and that such resolutions were duly adopted and have not been
amended or rescinded, (iii) an incumbency certificate dated as of the Effective
Date executed on behalf of Manhattan by its corporate secretary or one of its
assistant corporate secretaries certifying the signature and office of each
officer of Manhattan executing this Agreement, the Certificate of Merger or any
other agreement, certificate or other instrument executed pursuant hereto by
Manhattan, (iv) a copy of the Certificate of Incorporation of Manhattan,
certified by the Secretary of State of Delaware, and a certificate from the
Secretary of State of Delaware evidencing the good standing of Manhattan in such
jurisdiction.
(d) Consents and Approvals. Manhattan shall have obtained all
consents and approvals necessary to consummate the transactions contemplated by
this Agreement, including, without limitation, those set forth on Schedule 3.2,
in order that the transactions contemplated herein not constitute a breach or
violation of, or result in a right of termination or acceleration of,
38
or creation of any encumbrance on any of Manhattan's assets pursuant to the
provisions of, any agreement, arrangement or undertaking of or affecting
Manhattan or any license, franchise or permit of or affecting Manhattan.
(e) Dissenters' Rights. Holders of no more than two (2) percent of
the outstanding shares of Manhattan Common Stock shall have validly exercised,
or remained entitled to exercise, their appraisal rights under Section 262 of
the DGCL.
(f) Fairness Opinion. Atlantic shall have received a written opinion
addressed to it for inclusion in the Proxy Statement that the consideration to
be received by it in the Merger is fair to the stockholders of Atlantic from a
financial point of view, and that fairness opinion shall not have been revoked
or withdrawn.
(g) Merger Certificate. Manhattan shall have executed a copy of the
Certificate of Merger. (h) Stockholder Questionnaire. Each of the Manhattan
stockholders shall have executed and delivered to Atlantic a completed
Stockholder Questionnaire that is accurate in all material respects.
7.3 Additional Conditions to Obligation of Manhattan. The obligation of
Manhattan to consummate the transactions contemplated hereby in accordance with
the terms of this Agreement is also subject to the fulfillment or waiver of the
following conditions:
(a) Representations And Compliance. The representations of Atlantic
and MPAC contained in this Agreement were accurate as of the date of this
Agreement and are accurate as of the Effective Time, in all respects (in the
case of any representation containing any materiality qualification) or in all
material respects (in the case of any representation without any materiality
qualification). Atlantic and MPAC, respectively, shall in all material respects
have performed each obligation and agreement and complied with each covenant to
be performed and complied with by them hereunder at or prior to the Effective
Date.
(b) Officers' Certificate. Atlantic shall have furnished to
Manhattan a certificate of the Chief Executive Officer and the Chief Financial
Officer of Atlantic, dated as of the Effective Date, in which such officers
shall certify that, to their best Knowledge, the conditions set forth in Section
7.3(a) have been fulfilled.
(c) Secretary's Certificate. Atlantic shall have furnished to
Manhattan (i) copies of the text of the resolutions by which the corporate
action on the part of Atlantic necessary to approve this Agreement and the
Certificate of Merger, the election of the directors of Atlantic to serve
following the Effective Time and the transactions contemplated hereby and
thereby were taken, which shall be accompanied by a certificate of the corporate
secretary or assistant corporation secretary of Atlantic dated as of the
Effective Date certifying to Manhattan that such copies are true, correct and
complete copies of such resolutions and that such resolutions were duly adopted
and have not been amended or rescinded, (ii) an incumbency certificate dated as
of the Effective Date executed on behalf of Atlantic by its corporate secretary
or one of its assistant corporate secretaries certifying the signature and
office of each officer of Atlantic executing this Agreement, the Certificate of
Merger or any other agreement, certificate
39
or other instrument executed pursuant hereto, and (iii) a copy of the
Certificate of Incorporation of Atlantic, certified by the Secretary of State of
Delaware, and certificates from the Secretary of State of Delaware evidencing
the good standing of Atlantic in such jurisdiction.
(d) Consents and Approvals. Atlantic and MPAC shall have obtained
all consents and approvals necessary to consummate the transactions contemplated
by this Agreement, including, without limitation, those set forth on Schedule
4.2, in order that the transactions contemplated herein not constitute a breach
or violation of, or result in a right of termination or acceleration of, or
creation of any encumbrance on any of Atlantic's or MPAC's assets pursuant to
the provisions of, any agreement, arrangement or undertaking of or affecting
Atlantic or any Atlantic Subsidiary or any license, franchise or permit of or
affecting Atlantic or any Atlantic Subsidiary.
(e) Resignations. Each of the officers and non-continuing directors
of Atlantic immediately prior to the Effective Time shall deliver duly executed
resignations from their positions with Atlantic effective immediately after the
Effective Time.
(f) Atlantic Warrant Exchange. All of Atlantic's currently
outstanding warrants issued on or about December 3, 2001 to purchase an
aggregate of 9,166,649 shares of Atlantic Common Stock at $0.29 per share shall
have been exchanged for shares of Atlantic Common Stock on the basis of one (1)
share of Atlantic Common Stock for every three (3) warrants surrendered for
exchange.
ARTICLE VIII
TERMINATION, AMENDMENT AND WAIVER
8.1. Termination. This Agreement may be terminated prior to the Effective
Date:
(a) by mutual consent of Manhattan and Atlantic, if the Board of
Directors of each so determines by vote of a majority of the members of its
entire board;
(b) by Atlantic, if any representation of Manhattan set forth in
this Agreement was inaccurate when made or becomes inaccurate such that the
condition set forth in Section 7.2(a) could not be satisfied;
(c) by Manhattan if any representation of Atlantic set forth in this
Agreement was inaccurate when made or becomes inaccurate such that the condition
set forth in Section 7.3(a) could not be satisfied;
(d) by Atlantic if Manhattan fails to perform or comply with any of
the obligations that it is required to perform or to comply with under this
Agreement such that the condition set forth in Section 7.2(a) could not be
satisfied;
(e) by Manhattan if Atlantic fails to perform or comply with any of
the obligations that it is required to perform or to comply with under this
Agreement such that the condition set forth in Section 7.3(a) could not be
satisfied;
40
(f) by either Manhattan or Atlantic, if, following a vote by the
stockholders of each company at the Atlantic Stockholder Meeting and the
Manhattan Stockholder Meeting, the Merger and this Agreement are not duly
approved by the stockholders of each of Manhattan or Atlantic;
(g) by either Manhattan or Atlantic if the Effective Date is not on
or before February 7, 2003, or such later date as Manhattan and Atlantic may
mutually agree (unless the failure to consummate the Merger by such date shall
be due to the action or failure to act of the party seeking to terminate this
Agreement in breach of such party's obligations under this Agreement); or
(h) by either Atlantic or Manhattan pursuant to Section 6.3 above.
Any party desiring to terminate this Agreement shall give prior written
notice of such termination and the reasons therefor to the other party.
ARTICLE IX
GENERAL PROVISIONS
9.1 Notices. All notices and other communications hereunder shall be in
writing and shall be sufficiently given if made by hand delivery, by fax, by
telecopier, by overnight delivery service, or by registered or certified mail
(postage prepaid and return receipt requested) to the parties at the following
addresses (or at such other address for a party as shall be specified by it by
like notice):
If to Manhattan: Manhattan Pharmaceuticals, Inc.
787 Seventh Avenue, 48th Floor
New York, New York 10019
Facsimile: (212) 554-4355
Attn: Joshua A. Kazam
With copies to: Maslon Edelman Borman & Brand, LLP
90 South Seventh Street, Suite 3300
Minneapolis, MN 55402
Facsimile: (612) 642-8358
Attn: William M. Mower, Esq.
If to Atlantic Atlantic Technology Ventures, Inc.
or MPAC: 350 Fifth Avenue, Suite 5507
New York, New York 10118
Facsimile: (212) 267-2159
Attn: Frederic P. Zotos, President
With copies to: Kramer Levin Naftalis & Frankel LLP
919 Third Avenue
New York, NY 10022
Facsimile: (212) 715-8000
Attn: Ezra G. Levin, Esq.
41
All such notices and other communications shall be deemed to have been
duly given as follows: when delivered by hand, if personally delivered, when
received, if delivered by registered or certified mail (postage prepaid and
return receipt requested), when receipt acknowledged; if faxed or telecopied, on
the day of transmission or, if that day is not a business day, on the next
business day; and the next day delivery after being timely delivered to a
recognized overnight delivery service.
9.2 No Survival. The representations and warranties and obligations
contained in this Agreement will terminate at the Effective Time or on
termination of this Agreement in accordance with Section 8.1, except that the
obligations contained in Article II and any other obligation contained in this
Agreement requiring performance or compliance after the Effective Time
(including without limitation Section 6.3(c)) will survive the Effective Time
indefinitely.
9.3 Interpretation. The headings contained in this Agreement are for
reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement. References to Sections and Articles refer to
Sections and Articles of this Agreement unless otherwise stated. Words such as
"herein," "hereinafter," "hereof," "hereto," "hereby" and "hereunder," and words
of like import, unless the context requires otherwise, refer to this Agreement
(including the Exhibits and Schedules hereto). As used in this Agreement, the
masculine, feminine and neuter genders shall be deemed to include the others if
the context requires.
9.4 Severability. If any term, provision, covenant or restriction of this
Agreement is held by a court of competent jurisdiction to be invalid, void or
unenforceable, the remainder of the terms, provisions, covenants and
restrictions of this Agreement shall remain in full force and effect and shall
in no way be affected, impaired or invalidated, and the parties shall negotiate
in good faith to modify this Agreement and to preserve each party's anticipated
benefits under this Agreement.
9.5 Amendment. This Agreement may not be amended or modified except by an
instrument in writing approved by the parties to this Agreement and signed on
behalf of each of the parties hereto.
9.6 Waiver. At any time prior to the Effective Date, any party hereto may
(a) extend the time for the performance of any of the obligations or other acts
of the other party hereto or (b) waive compliance with any of the agreements of
the other party or with any conditions to its own obligations, in each case only
to the extent such obligations, agreements and conditions are intended for its
benefit. Any such extension or waiver shall only be effective if made in writing
and duly executed by the party giving such extension or waiver.
9.7 Miscellaneous. This Agreement (together with all other documents and
instruments referred to herein): (a) constitutes the entire agreement, and
supersedes all other prior agreements and undertakings, both written and oral,
among the parties, with respect to the subject matter hereof; and (b) shall be
binding upon and inure to the benefit of the parties hereto and their respective
successors and assigns, but shall not be assignable by either party hereto
without the prior written consent of the other party hereto.
42
9.8 Counterparts. This Agreement may be executed in any number of
counterparts, and each such counterpart shall be deemed to be an original
instrument, but all such counterparts together shall constitute but one
agreement.
9.9 Third Party Beneficiaries. Except as provided in the next following
sentence, each party hereto intends that this Agreement shall not benefit or
create any right or cause of action in or on behalf of any person other than the
parties hereto. The provisions of Section 6.16 are intended for the benefit of
the stockholders of Manhattan and their respective assigns.
9.10 Governing Law. This Agreement is governed by the internal laws of the
State of New York, except to the extent the mandatory law of the State of
Delaware applies.
9.11 Jurisdiction; Service of Process. Any action or proceeding seeking to
enforce any provision of, or based on any right arising out of, this Agreement
must be brought against any of the parties in the courts of the State of New
York, County of New York, or, if it has or can acquire jurisdiction, in the
United States District Court for the Southern District of New York, and each of
the parties consents to the jurisdiction of those courts (and of the appropriate
appellate courts) in any such action or proceeding and waives any objection to
venue laid therein. Process in any such action or proceeding may be served by
sending or delivering a copy of the process to the party to be served at the
address and in the manner provided for the giving of notices in Section 9.1.
Nothing in this Section 9.11, however, affects the right of any party to serve
legal process in any other manner permitted by law.
[Remainder of Page Left Intentionally Blank - Signature Page to Follow]
43
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed on the date first written above by their respective officers.
MANHATTAN PHARMACEUTICALS, INC.
By: /s/ John Knox
------------------------------------
Name: John Knox
Title: Treasurer
ATLANTIC TECHNOLOGY VENTURES, INC.
By: /s/ Frederick P. Zotos
------------------------------------
Name: Frederick P. Zotos
Title: President and Chief Executive
Officer
MANHATTAN PHARMACEUTICALS ACQUISITION CORP.
By: /s/ Frederick P. Zotos
------------------------------------
Name: Frederick P. Zotos
Title: President and Chief Executive
Officer
44
Exhibit 23.1
INDEPENDENT AUDITORS' REPORT
To the Board of Directors of:
Manhattan Pharmaceuticals, Inc.
(A development stage company)
We have audited the accompanying balance sheets of Manhattan Pharmaceuticals,
Inc. (a development stage company) as of September 30, 2002 and December 31,
2001 and the related statements of operations, changes in stockholders'
deficiency and cash flows for the nine months ended September 30, 2002, for the
period from August 6, 2001 (inception) to December 31, 2001 and for the period
from August 6, 2001 (inception) to September 30, 2002. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and
perform the audits to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly in all
material respects, the financial position of Manhattan Pharmaceuticals, Inc. as
of September 30, 2002 and December 31, 2001, and the results of its operations
and its cash flows for the nine months ended September 30, 2002, for the period
from August 6, 2001 (inception) to December 31, 2001 and for the period from
August 6, 2001 (inception) to September 30, 2002, in conformity with accounting
principles generally accepted in the United States of America.
The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. As discussed in Note 9 to the
financial statements, the Company has a net loss from operations of $892,365
since inception, a negative cash flow from operating activities of $626,721
since inception, a working capital deficiency of $839,482 and a stockholders'
deficiency of $830,776. These matters raise substantial doubt about the
Company's ability to continue as a going concern. Management's plan in regards
to these matters is so described in Note 9. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty.
/s/ WEINBERG & COMPANY, P.A.
Boca Raton, Florida
November 1, 2002